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1. Zusammenfassung 
Der Bradykinin B2 Rezeptor (B2R) gehört zur Familie der G-Protein-gekoppelten Rezeptoren (GPCRs, 
G protein-coupled receptors), die mit fast 1000 Vertretern die größte Familie der Membranrezeptoren 
darstellen. GPCRs interagieren nach der Aktivierung mit heterotrimeren G-Proteinen und induzieren 
bei ihnen den Austausch von GDP zu GTP. Die aktivierten G-Protein Untereinheiten (G!-GTP und 
G"#) können anschließend mit Effektorproteinen wechselwirken und so verschiedenste Vorgänge der 
Zellphysiologie regulieren. Der B2R wird nach der G-Protein-Aktivierung durch G-Protein-gekoppelte 
Rezeptorkinasen (GRKs) und „second messenger“-Kinasen phosphoryliert und interagiert mit "-
Arrestinen, was die weitere G-Protein Anlagerung verhindert und die Internalisierung des Rezeptors 
über sogenannte „Clathrin-coated-pits“ einleitet. Strukturell werden für den B2R, wie für alle GPCRs, 
sieben Transmembrandomänen, drei extrazelluläre und drei intrazelluläre Schleifen sowie ein 
intrazellulär lokalisierter C-Terminus postuliert (Abb.1). Neben den sieben helikalen 
Transmembrandomänen existiert noch eine weitere !-Helix (Helix 8), die im Anschluss an die siebte 
Transmembrandomäne zytosolisch und parallel zur Plasmamembran angeordnet ist und einen Teil des 
C-Terminus darstellt (Abb.1). 
In der vorliegenden Arbeit konnten wir zeigen, dass die Störung der Sekundärstruktur der Helix 8 
durch Deletion des C-Terminus oder durch die Mutation einer zentralen Aminosäure (Lys-315) zu 
einem Prolin (Helixbrecher) zu einer starken Abnahme der Oberflächenexpression des B2R führte. Der 
fehlerhafte Transport des Rezeptors zur Zellmembran konnte durch die Zugabe eines 
membrangängigen „small-molecule“ B2R Antagonisten (JSM10292) korrigiert werden. Folglich 
übernimmt die Helix 8 eine wichtige Aufgabe bei der Stabilisierung der für den Transport an die 
Plasmamembran notwendigen Rezeptorkonformation, die durch einen entsprechenden Antagonisten 
übernommen werden kann. In der vorliegenden Arbeit wird außerdem gezeigt, dass die strukturelle 
Integrität der Helix 8 und nicht, wie bisher allgemein angenommen, vor allem der C-Terminus (mit 
den Phosphorylierungsstellen) für die Internalisierung des B2R und seiner Interaktion mit GRK2/3 und 
"-Arrestin2 unerlässlich ist. Der C-Terminus ist jedoch für die stabile Interaktion von "-Arrestin1 mit 
dem B2R erforderlich. Obwohl die G-Protein-Aktivierung nach unseren Ergebnissen anscheinend auch 
über die Helix 8 vermittelt wird, konnten wir durch ein „alanine-screening“ der drei intrazellulären 
Schleifen belegen, dass wie erwartet vor allem hier die Rezeptordomänen liegen, die für eine 
produktive Interaktion mit den G-Proteinen entscheidend sind. Für den Prozess der Rezeptor-
Internalisierung ist der Beitrag der intrazellulären Schleifen im Gegensatz zur Rolle der Helix 8 
vermutlich nur von untergeordneter Bedeutung. 
Zusammenfassend zeigen die Ergebnisse der Arbeit erstmalig, dass die Helix 8 eine strukturelle 
Einheit darstellt, deren Integrität neben ihrer Funktion für den Transport des B2Rs zur Plasmamembran 
eine entscheidende Rolle für die Aktivierung und die Rekrutierung von intrazellulären Proteinen 
spielt, die an der Signaltransduktion und der Internalisierung des Rezeptors beteiligt sind. Durch die 
Generierung von Rezeptorchimären aus B2R und anderen GPCRs konnten wir darüber hinaus zeigen, 
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dass die Helix 8 auch bei anderen GPCRs eine entsprechend tragende Funktion bei Transport, 
Signaltransduktion und Internalisierung hat. 
2. Summary 
The bradykinin B2 Receptor (B2R) belongs to the family of G protein-coupled receptors (GPCRs), 
which comprises the largest class of membrane receptors (approx. 1000 members). Upon activation 
GPCRs bind to heterotrimeric G proteins and cause their exchange of GDP for GTP. The activated G 
protein subunits (G!-GTP und G"#) can then interact with downstream effectors to modulate various 
aspects of cellular signaling. Subsequent to G protein activation the B2R becomes phosphorylated 
through G protein-coupled receptor kinases (GRKs) and second messenger kinases and interacts with 
"-arrestins, thereby preventing further G protein binding and promoting receptor internerlization via 
clathrin-coated-pits. Like all other GPCRs, the B2R exhibits a seven transmembrane helix topology, 
with three extracellular and three intracellular loops as well as a cytosolic C-terminus. Moreover, the 
B2R shows an intracellular !-helix (Helix 8) that is linked to transmembrane helix 7 and placed 
parallel to the plasmamembrane being a part of the C-terminus. 
We show here that disruption of helix 8 in the B2R by either C-terminal deletion or just by mutation of 
a central amino acid (lys-315) to a helix-breaking proline resulted in strong reduction of surface 
expression. Interestingly, this malfunction could be overcome by addition of the membrane-permeable 
B2R antagonist JSM10292, suggesting that helix 8 has a general role for conformational stabilization 
that can be accounted for by an appropriate antagonist. Intriguingly, an intact helix 8, but not the C-
terminus with its phosphorylation sites, was indispensable for receptor internalization and for 
interaction of the B2R with GRK2/3 and "-arrestin2. Recruitment of "-arrestin1, however, required the 
presence of the C-terminus. Although G protein activation is mediated in part through the action of 
helix 8 we could also show the special importance of the intracellular loops for the productive 
interaction with G proteins by using an alanine-screening approach. However, in contrast to helix 8 the 
intracellular loops are obviously not essential for receptor internalization. 
Taken together, our results demonstrate for the first time that helix 8 of the B2R plays a crucial role not 
only in efficient trafficking to the plasma membrane but also for the interaction and activation of 
intracellular proteins that promote signaling and internalization. Additional data obtained with chimera 
of B2R with other GPCRs suggest that helix 8 might have similar functions in other GPCRs, too. 
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3. Grundlegendes zur Struktur und molekularen Regulation von GPCRs am Beispiel des B2 
Bradykinin Rezeptors 
G-Protein-gekoppelte Rezeptoren (GPCRs) stellen mit fast 1000 Vertretern die größte Familie der 
Membranrezeptoren dar und sind maßgeblich an der Regulation von vielen zellphysiologischen 
Vorgängen beteiligt. Strukturell zeichnen sich GPCRs durch sieben Transmembranhelices (TM 1-7) 
aus, die durch drei extrazelluläre (ECL 1-3; extracellular loops) und drei intrazelluläre (ICL 1-3; 
intracellular loops) Schleifen miteinander verbunden sind (Palczewski et al., 2000) (Abb.1). Die 
Aufklärung der Struktur mehrerer GPCRs hat ergeben, dass noch eine weitere !-Helix (Helix 8) 
existiert, die im Anschluss an die hoch konservierte NPXXY 1 -Sequenz der siebten 
Transmembranhelix (TM7) parallel zur Plasmamembran angeordnet ist und einen Teil des C-
Terminus darstellt (Huynh et al., 2009) (Abb.1). Diese !-Helix zeichnet sich allgemein durch einen 
ausgeprägt amphipathischen Charakter aus, wobei der hydrophobe Teil der lipophilen Zellmembran 
zugewandt ist und die hydrophile Seite in Richtung Zytosol zeigt. Bei vielen GPCRs, so auch im B2R, 
wird die Helix 8 an ihrem Ende durch acylierte Cysteine in der Membran verankert (z.B. durch 
Palmitinsäure) und somit in Position gehalten (Abb.1). Bei Säugetieren unterscheidet man drei 
verschiedene Familien von G-Protein-gekoppelten Rezeptoren (A, B und C), die sich hauptsächlich in 
der Länge einzelner Domänen (Schleifen, N- und C-Terminus) sowie in der speziesübergreifenden 
Konservierung einzelner Aminosäuren unterscheiden (Gether, 2000).  
 
Abb.1. Schematische Darstellung 
der Struktur eines typischen G-
Protein-gekoppelten Rezeptors 
(Familie A). Dargestellt sind die 
sieben Transmembrandomänen (1-7) 
sowie die drei extrazellulären (ECL 
1-3) und drei intrazellulären 
Schleifen (ICL 1-3). Die Helix 8 
liegt horizontal zur Plasmamembran 
und wird durch mit Palmitinsäure 
(schwarze Balken) acylierte Cysteine 
in der Plasmamembran fixiert. Am 
Ende von TM 3 und TM 7 befinden 
sich die hoch konservierte DRY- 
bzw. NPxxY-Sequenz. 
 
Der B2 Bradykinin Rezeptor (B2R) gehört zur Familie A der GPCRs und wird ubiquitär in 
verschiedenen Zellen (z.B. Endothelzellen, glatte Muskelzellen, Fibroblasten, Nervenzellen und 
verschiedenen Tumorzellen) exprimiert (Leeb-Lundberg et al., 2005). Er ist ein wesentlicher 
Bestandteil des Kallikrein-Kinin-Systems und dabei insbesondere an der Regulation vaskulärer und 
inflammatorischer Prozesse beteiligt. Kallikreine sind Serinproteasen die aus ihrem Substrat, den 
Kininogenen, die von der Leber synthetisiert und in den Blutkreislauf sezerniert werden durch 
limitierte Proteolyse die Kinine (Bradykinin (BK) und Kallidin (KD)) freisetzen. Kallidin 
                                                      
%!X: eine beliebige proteinogene Aminosäure 
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unterscheidet sich vom Nonapeptid Bradykinin lediglich durch ein zusätzliches N-terminales Lysin 
weswegen es auch als Lys-BK bezeichnet wird. Diese beiden Peptide binden spezifisch an den B2 
Rezeptor und lösen in den Zielzellen die entsprechenden biologischen Effekte aus (z.B. 
Gefäßerweiterung, Erhöhung der Gefäßpermeabilität und Schmerzweiterleitung).  
 
Nach der Aktivierung durch Hormone (z.B. Bradykinin beim B2R), Neurotransmitter oder 
physikalischen Reizen wird bei GPCRs eine Konformationsänderung ausgelöst die zur intrazellulären 
Bindung von heterotrimeren G-Proteinen führt. Aktivierte GPCRs sind Guanin-Nukleotid-
Austauschfaktoren für die G!-Untereinheit der G-Proteine und bewirken bei diesen den Austausch 
von GDP zu GTP (Abb. 2, Aktivierung & Signaltransduktion), was zu ihrer Aktivierung führt. Die 
aktiven G-Protein Untereinheiten (G!-GTP und G"#) können anschließend mit Effektorproteinen (z.B. 
Adenylatzyklase oder Phospholipasen) interagieren und so verschiedenste Vorgänge der 
Zellphysiologie modulieren. 
 
Liganden-aktivierte GPCRs binden neben G-Proteinen auch sogenannte G-Protein-gekoppelte 
Rezeptorkinasen (GRKs) und werden von diesen phosphoryliert (Reiter et al., 2006). Es sind 
insgesamt sieben verschiedene Subtypen von GRKs bekannt (GRK 1-7), die in verschiedenen 
Geweben exprimiert werden und unterschiedliche Präferenzen für bestimmte GPCRs aufweisen. Die 
Phosphorylierung von GPCRs durch GRKs führt zu einer verstärkten Interaktion mit Arrestinen - eine 
Gruppe von Gerüstproteinen (Arrestin 1-4), die ebenfalls in verschiedenen Geweben exprimiert 
werden. Die im Gegensatz zu Arrestin1 und 4 (nur in Netzhautzellen) ubiquitär auftretenden Arrestine 
2 und 3 werden auch als "-Arrestin 1 und 2 bezeichnet, weil ihre Funktion erstmals im 
Zusammenhang mit den "-Adrenergen Rezeptoren aufgeklärt wurde. Im Folgenden soll ausschließlich 
die letztere Bezeichnung Verwendung finden. 
Die Interaktion von GPCRs mit "-Arrestinen verhindert zum einen die weitere Anlagerung und 
Aktivierung von G-Proteinen und führt zum anderen bei vielen GPCRs zu einer "-Arrestin-
vermittelten Internalisierung (Abb. 2) des Rezeptor in sogenannten „clathrin-coated-pits“ (Reiter et al., 
2006). Dieser Prozess der Signalabschwächung, der auch als Desensitisierung bezeichnet wird, spielt 
eine wichtige Rolle bei der Feinregulation der Aktivität von GPCRs. Forschungsergebnisse der letzten 
Jahre zeigen, dass die vom Rezeptor rekrutierten "-Arrestine neben ihrer Funktion als Adaptorproteine 
für die Internalisierung des Rezeptors auch als Gerüstproteine zur Aktivierung G-Protein-
unabhängiger Signalwege wie z.B. dem MAP-Kinase-Weg (MAP, mitogen-activated protein) dienen.  
Nach der Internalisierung werden die Rezeptorproteine entweder in den Lysosomen der Zelle abgebaut 
(Degradation) oder zurück an die Zelloberfläche transportiert, um erneut für (weitere) Stimulationen 
zur Verfügung zu stehen (Recycling) (Abb. 2). Wie dies genau gesteuert wird und wodurch das 
weitere Schicksal eines Rezeptors entschieden wird, ist im Detail noch nicht geklärt.  
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Abb2. Klassischer Regulationsmechanismus von GPCRs, der so auch für den B2 Bradykinin Rezeptor gültig ist. 
PIP2/PIP3: Phosphatidylinositolbisphosphat/-trisphosphat; AP-2: Adaptorprotein-2 (modifiziert nach (Moore et 
al., 2007)).  
3.1. Die Rolle der intrazellulären Domänen für die Regulation des B2 Bradykinin Rezeptors 
Obwohl die grundlegenden Mechanismen der Signaltransduktion und der Regulation des B2R 
weitestgehend untersucht wurden, ist die Information zu den molekularen und strukturellen 
Wechselwirkungen zwischen Rezeptor und den intrazellulären Kopplungsproteinen noch ziemlich 
begrenzt. Welche intrazellulären Elemente des B2R (ICLs, Helix 8, C-Terminus) hierbei eine 
Schlüsselrolle als Interaktionspartner für die G-Proteine, die GRKs und die "-Arrestine einnehmen, ist 
noch nicht geklärt. 
3.1.1. Die Funktion der Helix 8 für die Rezeptor-Oberflächenexpression 
Für Rhodopsin sowie für den muskarinischen M3 Acetylcholin-Rezeptor konnten als Folge der 
Aktivierung Konformationsänderungen mit einer deutlichen räumlichen Verschiebung der Helix 8 
gezeigt werden (Altenbach et al., 2001; Li et al., 2007). Diese Ergebnisse legen den Schluss nahe, 
dass diese Helix ein mögliches Schlüsselelement für die Weiterleitung von Informationen in die Zelle 
ist. Um die genaue Funktion des C-Terminus aber insbesondere der Helix 8 für die Regulation des 
B2R zu entschlüsseln (Publikation A) wurden im Rahmen der Doktorarbeit mehrere Rezeptormutanten 
mit sukzessiv verkürztem C-Terminus in HEK (human embryonic kidney) 293 Zellen exprimiert. 
Zusätzlich generierten wir eine Mutante bei der die strukturelle Integrität der Helix 8 gestört wurde, 
indem eine zentrale Aminosäure (Lys-315) innerhalb der Helix 8-Sequenz gegen den Helixbrecher 
! ( 
Prolin ausgetauscht wurde. Mithilfe des gelb fluoreszierenden Proteins (YFP, yellow fluorescent 
protein) das erstmalig am N-Terminus des B2R angefügt wurde, um die Funktion des C-Terminus 
nicht zu beeinträchtigen, konnte gezeigt werden, dass alle Mutationen oder Deletionen, welche die 
Struktur der Helix 8 (zer)störten, zu einer starken intrazellulären Akkumulation der YFP-B2R-
Fusionskonstrukte führten. Gleichzeitig wurden diese Mutanten nur unvollständig glykosyliert, was 
vermutlich für ihr Verbleiben im endoplasmatischen Retikulum (ER) verantwortlich ist. Die 
Zurückhaltung von GPCRs durch das Qualitätskontrollsystem des ER nach Mutation oder Deletion 
der entsprechenden Helix 8-Sequenzen kann entweder durch die unkorrekte Faltung des 
Rezeptorproteins (Thielen et al., 2005; Yasuda et al., 2009) oder das Fehlen von spezifischen 
Sequenzmotiven (Bermak et al., 2001) ausgelöst werden. Wir konnten zeigen, dass der verminderte 
Transport an die Plasmamembran durch die Anwendung eines membrangängigen „small-molecule“ 
B2R Antagonisten (JSM10292) korrigiert werden konnte. Daher gehen wir davon aus dass, die Helix 8 
eine wichtige Aufgabe für die Stabilisierung der für den Transport an die Zellmembran notwendigen 
Rezeptorkonformation hat. Die Stabilisierung dieser Konformation kann offensichtlich auch durch 
einen entsprechenden Antagonisten, der dabei als sogenanntes „pharmakologisches Chaperon“ wirkt, 
übernommen werden. 
3.1.2. Die Helix 8 als Vermittlerin der Rezeptor-Internalisierung 
Wie oben bereits erwähnt, werden GPCRs spezifisch von GPCR Kinasen (GRKs) phosphoryliert. Ein 
wesentlicher Unterschied zwischen GRKs und anderen Kinasen ist die Tatsache, dass erstere keine 
genau definierten Konsensus-Sequenzen erkennen, jedoch unmittelbar vom Funktionszustand des 
Rezeptors abhängig sind: GRKs phosphorylieren ausschließlich liganden-aktivierte Rezeptoren. 
Obwohl die Zielsequenzen für die Phosphorylierung (Serine und Threonine im C-Terminus) beim B2R 
bereits identifiziert wurden (Blaukat et al., 2001), war bisher noch nichts über die anderen 
Rezeptorinteraktionsstellen für GRKs und ihre Spezifität für den B2R bekannt.  
Um die Spezifität der verschiedenen GRKs für den B2R zu identifizieren, untersuchten wir den 
Einfluss der Überexpression von GRK 2-6 auf die Hemmung des MAP-Kinase-Signalweges (ERK1/2 
Phosphorylierung) nach Stimulation mit dem Agonisten Bradykinin. Die ERK1/2 Phosphorylierung 
konnte nur durch Überexpression von GRK2 und GRK3 signifikant gehemmt werden. GRK1 und 
GRK7 wurden hierbei nicht untersucht, da sie ausschließlich in Netzhautzellen vorkommen und daher 
keine physiologische Relevanz für die Regulation des B2R besitzen. Neben der Spezifität des B2R für 
GRK2 und 3 konnten wir durch Co-Immunopräzipitation zeigen, dass die Interaktion mit diesen 
GRKs hauptsächlich von der Helix 8 und nicht vom C-Terminus und dessen Phosphorylierungsstellen 
bestimmt wird. 
Die spezifische Phosphorylierung des B2R galt bisher als wesentliche Voraussetzung für die 
Interaktion mit den "-Arrestinen und die anschließende Rezeptorinternalisierung. Außerhalb der 
Netzhaut gibt es zwei verschiedene !-Arrestin Subtypen (!-Arrestin1 und 2). Für den B2R wurden 
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bisher jedoch keine funktionellen Unterschiede dieser beiden Formen beschrieben. In der vorliegenden 
Arbeit konnte gezeigt werden, dass die Rezeptorinternalisierung I: unabhängig von der Präsenz des C-
Terminus II: subtyp-spezifisch durch !-Arrestin2 und III: maßgeblich durch die Helix 8 vermittelt 
wird. "-Arrestin1 kann unter bestimmten Umständen (Überexpression, siRNA-knockdown von "-
Arrestin2) die Funktion von "-Arrestin2 für die Internalisierung des B2R übernehmen, spielt aber unter 
„quasi-physiologischen“ Bedingungen in HEK 293 Zellen eine untergeordnete Rolle für diesen 
Prozess. Anders als für "-Arrestin2 erfordert die stabile Bindung von "-Arrestin1 an den B2R 
zwingend die Phosphorylierung des C-Terminus. 
Mithilfe verschiedener Rezeptorchimären, bestehend aus dem B2R und der Helix 8 und/oder dem C-
Terminus verschiedener GPCRs (PAR 2, "2-AR, AT1R, B1R)2, konnten wir außerdem zeigen, dass die 
Helix 8 nur in ihrer Rezeptor-spezifischen Umgebung die Funktion als Vermittlerin der 
Rezeptorinternalisierung erfüllen kann. Der restliche C-Terminus hingegen war in diesem 
Zusammenhang beliebig austauschbar und funktionierte auch unabhängig von seinem eigentlichen 
Rezeptor-Grundgerüst.  
3.1.3. Die Funktion der intrazellulären Domänen für die G-Protein Aktivierung 
Die Tatsache, dass alle Helix 8-Mutanten in der Lage waren das G-Protein zu aktivieren, wenngleich 
mit einer starken Erhöhung der EC50-Werte, bestätigte unsere Ergebnisse, dass auch andere 
intrazelluläre Bereiche außerhalb der Helix 8 als Interaktionsstellen für das G-Protein fungieren. 
Mithilfe eines „alanine-screenings“ der drei intrazellulären Schleifen (z.T. als Gruppen von 3-5 
Aminosäuren, z.T als Punktmutationen) und durch die anschließende Bestimmung der 
Inositolphosphat-Freisetzung (als Maß für die G-Protein-Aktivierung) konnten wir entsprechende 
Bereiche identifizieren (Publikation B). Hierbei waren bestimmte Sequenzen der dritten Schleife für 
die Aufrechterhaltung des inaktiven Grundzustands des Rezeptors wichtig, da die entsprechenden 
Alanin-Mutationen eine „semi-aktive“ Konformation induzierten, die auch durch die Zugabe von 
neutralen Antagonisten aktiviert werden konnte. Mutationen innerhalb der zweiten Schleife 
verursachten eine Abnahme der Inositolphosphat-Freisetzung und erwiesen sich deshalb als wichtige 
Determinanten für die produktive Interaktion mit dem G-Protein. Im Gegensatz zur Helix 8 war die 
Bedeutung der intrazellulären Schleifen für den Prozess der Rezeptor-Internalisierung allerdings 
gering. 
Die hoch konservierte DRY-Sequenz des B2R (siehe Abb.1), die sich durch alle Klassen der GPCRs 
zieht spielt eine wichtige Rolle für die Aufrechterhaltung des inaktiven Rezeptorzustands (Rovati et 
al., 2007). Vermutlich koordiniert sie intramolekulare Bindungen, die nach Ligandenbindung 
aufgebrochen werden, um eine entsprechende Änderung zur aktiven Konformation zu ermöglichen. 
Eine von uns generierte Alanin-Dreifachmutante (DRY"AAA), wurde nicht an der Oberfläche 
                                                      
"!PAR 2, Protease-aktivierter Rezeptor 2; "2-AR, "2-Adrenerger Rezeptor; AT1R, Angiotensin II Typ 1 
Rezeptor; B1R, Bradykinin B1 Rezeptor. 
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exprimiert, weshalb ihre Funktion für die G-Protein-Kopplung nicht weiter untersucht werden konnte. 
Durch eine für die vorliegende Arbeit etablierte Deglykosylierungs- und Immunoblot-Methode konnte 
gezeigt werden, dass diese Mutante zumindest in HEK 293 Zellen unvollständig glykosyliert wird und 
wahrscheinlich deshalb von der Qualitätskontrolle im ER zurückgehalten wird. 
Die Interpretation aller Daten, legt einen Mechanismus nahe, bei dem die Konformationsänderung des 
B2R nach Bindung eines Agonisten eine Bewegung der Helix 8 einschließt, die zu einer Freilegung 
von intrazellulären Rezeptorelementen führt, die dem G-Protein vor der Aktivierung noch nicht 
ausreichend zugänglich sind. Die vor kurzem aufgeklärte Struktur eines aktivierten "2-Adrenergen 
Rezeptors mit gebundenem G-Protein G!s zeigt allerdings keinerlei Berührung zwischen der Helix 8 
des Rezeptors und dem G-Protein (Rasmussen et al., 2011). Da diese Struktur aber gewissermaßen 
den Endzustand darstellt, schließt dies eine Interaktion der beiden Elemente während des 
Aktivierungsprozesses nicht unbedingt aus. 
 
Zusammenfassend zeigen unsere Ergebnisse, dass die Helix 8 eine strukturelle Einheit darstellt, deren 
Integrität neben dem Transport des Rezeptorproteins zur Plasmamembran eine entscheidende Rolle für 
die Aktivierung und die Bindung von intrazellulären Proteinen spielt, die an der Signaltransduktion 
und der Sequestrierung des B2R beteiligt sind. Ob die Helix 8 hierbei als direkter Interaktionspartner 
für die angesprochenen Proteine dient und/oder indirekt über die Stabilisierung der 
Gesamtrezeptorkonformation wirkt, muss durch zukünftige Experimente geklärt werden. Durch die 
Generierung von Rezeptorchimären aus dem B2R und verschiedenen GPCRs konnten wir jedoch 
zeigen, dass entsprechende Funktionen der Helix 8 auf für andere GPCRs gelten.  
4. Medizinische Bedeutung der Arbeit 
Derzeit entfalten ca. 50% aller auf dem Markt befindlichen Arzneistoffe ihre Wirkung direkt oder 
indirekt über GPCRs. Dennoch sind unsere Kenntnisse der molekularen Grundlagen für die 
Regulation von GPCRs immer noch begrenzt. Um pharmakologisch noch gezielter in die 
Signaltransduktion und damit in die Zellfunktion eingreifen zu können, bedarf es der Aufklärung von 
Unterschieden und Gemeinsamkeiten der molekularen Regulationsmechanismen dieser wichtigen 
Klasse von Membranrezeptoren. Von besonderer Bedeutung ist dabei die Beteiligung der 
verschiedenen GRK- und Arrestin-Subtypen, die diese Unterschiede mitbestimmen. Genauere 
Informationen zu den molekularen Interaktionsstellen und Sequenzmotiven des Rezeptors, die nach 
der Ligandenstimulation als Kontaktstelle für das G-Protein oder der GRKs und "-Arrestine dienen, 
wären von großem Nutzen. Die Bedeutung entsprechender Erkenntnisse zur Entwicklung neuer 
Arzneistoffklassen für GPCRs zeigt sich darin, dass insbesondere die GRKs und "-Arrestine an der 
Regulation der Anzahl von Rezeptormolekülen an der Zelloberfläche durch Prozesse wie 
Internalisierung, Down-Regulation und Recycling beteiligt sind und damit wesentlich über die Dauer 
und Stärke der Signaltransduktion entscheiden. Die Idee verschiedene Signalwege gezielt, d. h. 
! %+ 
unabhängig voneinander, pharmakologisch beeinflussen zu können, führte in den letzten Jahren 
verstärkt zu Bemühungen, Rezeptor(ant)agonisten („biased-(ant)agonists“) zu entwickeln, die gezielt 
den G-Protein- oder den "-Arrestin-vermittelten Signalweg (MAP-Kinase-Weg) aktivieren oder 
inhibieren (Reiter et al., 2012).  
Im Zusammenhang mit den hier präsentierten Ergebnissen ist es von großem Interesse, dass jüngst 
kleine chemische Moleküle identifiziert wurden, die an die Helix 8 binden und so allosterisch die 
Regulation von GPCRs und deren physiologische Funktionen beeinflussen können (Andrews et al., 
2008; Dowal et al., 2011). Solche Moleküle könnten neben den klassischen orthosterischen Liganden 
einen neuen Ansatz zur Entwicklung spezifischerer Arzneistoffe darstellen. 
  
Die Inaktivierung bzw. der Abbau von Bradykinin erfolgt über das Angiotensin converting enzyme 
(ACE), wodurch das Kallikrein-Kinin-System mit dem Renin-Angiotensin-Aldosteron System 
(RAAS) vernetzt ist. Ursprünglich wurden die kardio- und renoprotektiven Wirkungen der ACE-
Hemmer (z.B. Captopril, Ramipril) v.a. mit der Hemmung der Umwandlung von Angiotensin I zum 
stark vasokonstriktorisch und damit blutdrucksteigernd wirkenden Angiotensin II erklärt. Mittlerweile 
ist bekannt, dass diese Effekte auch durch den verminderten Abbau von Bradykinin und der damit 
verbundenen Gefäßentlastung mitbestimmt werden (Alhenc-Gelas et al., 2011). Die den Kininen hier 
zugeschriebenen kardio- und renoprotektiven Effekte stellen darüber hinaus einen vielversprechenden 
Ansatzpunkt für die Entwicklung spezifischer B2R Agonisten zur Behandlung von 
Herzkreislauferkrankungen und Diabetes dar. Um solche Arzneistoffe in die klinische Entwicklung zu 
bringen, sind genauere Kenntnisse über die Feinabstimmung der B2R Regulation notwendig, die u.a. 
wie in der vorliegenden Arbeit gezeigt anhand von in-vitro Zellmodellen gewonnen werden können. 
Das hereditäre Angioödem, eine seltene Erbkrankheit, die mit einer plötzlich auftretenden, 
Bradykinin-vermittelten lebensbedrohlichen Erweiterung der Blutgefäße einhergeht, wird bereits 
durch Anwendung eines spezifischen B2R-Antagonisten (Icatibant) behandelt, was die medizinische 
Relevanz des besprochenen Themengebiets zusätzlich verdeutlicht (Greve et al., 2011). 
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Upon activation the human bradykinin B2 receptor (B2R) acts
as guanine nucleotide exchange factor for the G proteins Gq/11
andGi. Thereafter, it gets phosphorylated by G protein-coupled
receptor kinases (GRKs) and recruits !-arrestins, which block
further G protein activation and promote B2R internalization
via clathrin-coated pits. As for most G protein-coupled recep-
tors of family A, an intracellular helix 8 after transmembrane
domain 7 is also predicted for the B2R. We show here that dis-
ruption of helix 8 in the B2R by either C-terminal truncation or
just by mutation of a central amino acid (Lys-315) to a helix-
breaking proline resulted in strong reduction of surface expres-
sion. Interestingly, this malfunction could be overcome by
the addition of the membrane-permeable B2R antagonist
JSM10292, suggesting that helix 8 has a general role for confor-
mational stabilization that can be accounted for by an appropri-
ate antagonist. Intriguingly, an intact helix 8, but not the C ter-
minus with its phosphorylation sites, was indispensable for
receptor sequestration and for interaction of the B2R with
GRK2/3 and !-arrestin2 as shown by co-immunoprecipitation.
Recruitment of !-arrestin1, however, required the presence of
the C terminus. Taken together, our results demonstrate that
helix 8 of the B2R plays a crucial role not only in efficient traf-
ficking to the plasma membrane or the activation of G proteins
but also for the interaction of the B2RwithGRK2/3 and!-arres-
tins. Additional data obtained with chimera of B2Rwith other G
protein-coupled receptors of family A suggest that helix 8might
have similar functions in other GPCRs as well.
The human bradykinin B2 receptor (B2R)2 belongs to the
family A (rhodopsin/!-adrenergic-like) of G protein-coupled
receptors (GPCRs). The B2R is ubiquitously expressed in many
cells and tissues, and its activation results in a variety of physi-
ological effects that range from vasodilatation and increased
vascular permeability to hyperalgesia and natriuresis (1).
Recent studies with B2R knock-out mice also point to a protec-
tive role of the B2R in the process of aging and in diabetes (2).
After extracellular binding of its endogenous agonists, of the
nona-peptide bradykinin (BK), or of kallidin (Lys-BK), the B2R
undergoes conformational changes that turn it into a guanine
nucleotide exchange factor for theGproteinsGq/11 andGi, thus
leading to the activation of G protein-dependent signaling cas-
cades. Among other events, this results in phosphatidylinositol
hydrolysis and activation of MAPK pathways. As reported for
many GPCRs, desensitization of the B2R comes along with
phosphorylation of serine/threonine residues in its C terminus
by G protein-coupled receptor kinases (GRKs) or second mes-
senger kinases as well as recruitment of !-arrestins and ends
with the sequestration of the receptor into intracellular com-
partments (1). Upon short term stimulation the receptor gets
recycled to the plasma membrane, whereas long term stimula-
tion leads to the down-regulation of the receptor (3–5). Cur-
rently, only limited information is available on the molecular
regulation of the B2R interactionswith theGproteins, GRKs, or
arrestins. Thus, it is not clear whether the same or different
domains of the B2R convey the active state of the receptor and
are involved in coupling of the various signaling proteins.
As a typical GPCR of family A, the B2R contains the NPXXY
sequence at the end of helix 7 and most likely the intracellular
helix 8, linked at the N terminus to the NPXXY sequence by a
four-amino acid spacer and anchored at its C terminus through
palmitoylated cysteines to the inner leaflet of the plasmamem-
brane. Helix 8 was first identified in the crystal structure of
bovine rhodopsin (6) and later, with the exception of CXCR4,
(7) also in the other resolved structures of GPCRs (8). It lies
perpendicular to the seven-transmembrane domain bundle of
GPCRs and has been reported to move significantly upon
receptor activation (9, 10). Therefore, helix 8 is an excellent
candidate for the agonist-induced recognition of and interac-
tion with cytosolic binding partners and has been studied
extensively in several GPCRs. Studies have not only shown the
involvement of helix 8 in G protein activation (11–15) but also
identified hydrophobic residues in helix 8 as essential for the
surface expression of the GPCRs investigated (11, 16, 17). In
addition, it has been published only recently that mutation of
positively charged residues in helix 8 of the thyrotropin releas-
ing hormone receptor prevented GRK-mediated receptor
phosphorylation (18).
As demonstrated by our research group,mutation of Tyr7.53
(Ballesteros/Weinstein nomenclature (19)) to an alanine in the
NPXXY sequence resulted in constitutive receptor phosphoryl-
ation and internalization (20). Homology modeling indicated
that Tyr7.53 in the B2R exerts an aromatic stacking interaction
with the highly conserved phenylalanine Phe7.60 in helix 8.
Thus, we speculated that the properties of mutant Tyr7.53 are
!S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1 and S2.
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caused by a modified interaction with GRKs and arrestins
involving helix 8. Further studies using chimera of the B2R with
the non-sequestering bradykinin B1 receptor also suggested
that helix 8might be involved directly or indirectly in the inter-
action of the B2R with GRKs and !-arrestins (21).
Consequently, we investigated in the present study not only
the function of helix 8 in the B2R with regard to surface expres-
sion and G protein activation but also assessed its role in the
desensitization process involving the interaction with GRKs
and !-arrestins. Our results clearly demonstrate that helix 8 is
involved in all of the before-mentioned receptor-dependent
processes, however, to a different degree and with different
requirements for the receptor microenvironment comprising
helix 8.
EXPERIMENTAL PROCEDURES
Materials—Flp-InTM TREx-293 (HEK 293) cells, and Opti-
MEM I serum-free medium were obtained from Invitrogen.
[2,3-Prolyl-3,4-3H]bradykinin (80 Ci/mmol) and myo-2-[3H]i-
nositol (22 Ci/mmol) were from PerkinElmer Life Sciences.
Vectors harboring the genes of GRK2–6 were kindly provided
byDr. A. de Blasi (University of Rome), and a vector comprising
the gene of the human !2-adrenergic receptor was provided by
Dr. M. J. Lohse (University of Würzburg). All other receptor
sequences were obtained from the Missouri S&T cDNA
Resource Center. Bradykinin was purchased from Bachem
(Weil am Rhein, Germany). The B2R antagonist JSM10292 was
a generous gift from the Jerini AG (Berlin, Germany). Roche
Applied Science delivered FuGENEHD, completemini EDTA-
free protease inhibitor tablets, and the rat monoclonal anti-
hemagglutinin (HA)-peroxidase high affinity antibody (3F10).
EcoTransfect was purchased from OzBiosciences (Marseille,
France). EZview red anti-HA affinity gel was bought from
Sigma. Cell culture reagents were obtained from PAA Labora-
tories (Cölbe, Germany). Monoclonal mouse anti-!-arrestin1
antibody and polyclonal rabbit anti-!-arrestin2 antibody were
from BD Transduction Laboratories and Millipore (Billerica,
MA), respectively. Rabbit polyclonal anti-GRK3 antibody (sc-
563; C-14) was from Santa Cruz Biotechnology, Inc. (Heidel-
berg, Germany). Two sets of siRNAs fromQiagen (Hilden, Ger-
many) were used. The first set was predesigned HP-validated
FlexiTube !-arrestin siRNAs: !-arrestin1 (catalog no.
SI02776921, 5!-CGACGUUCUGCAAGGUCUATT-3!) and
!-arrestin2 (catalog no. SI02776928, 5!-CGAACAAGAU-
GACCAGGUATT-3!). The second set was published siRNAs
(22): !-arrestin1 (5!-AGCCUUCUGCGCGGAGAAUTT-3)
and !-arrestin2 (5!-GGACCGCAAAGUGUUUGUGTT-3!).
HiPerFect transfection reagent was acquired fromQiagen. The
cross-linking agent dithiobis[succinimidylpropionate] (DSP)
was purchased from Pierce.
Gene Mutagenesis and Expression of Constructs—Standard
PCR techniques with appropriate primers were used to gener-
ate mutants of the B2R, of GRK3, and the receptor chimeras.
Coding sequences of theB2R and the respectivemutants started
with the third encoded methionine (23). Receptor constructs,
GRK3, !-arrestin1, and !-arrestin2 genes were all cloned into
the HindIII and the XhoI sites of the pcDNA5/FRT/TO vector
(Invitrogen). The receptor sequences were preceded at the N
terminus by a single hemagglutinin tag (MGYPYDVPDYAGS)
with the last two amino acids (Gly-Ser) of the tag being gener-
ated by the insertion of a BamHI site. For the N-terminal eYFP
(enhanced yellow fluorescent protein) fusion constructs, the
receptors were preceded by the signal sequence of the human
frizzled receptor 4 followed by the coding sequence for the
eYFP and the HA tag.
Cell Culture and Transfection—For stable expression of the
constructs in HEK 293 cells we used the Flp-In system from
Invitrogen as described previously (24). For transient transfec-
tion cells were seeded into 24 wells (80% confluency) and trans-
fected using 0.2 "g of DNA and 0.4 "l of EcoTransfect. Expres-
sion was induced with 0.5 "g/ml tetracycline 5–6 h after
transfection and 16 h before the respective assay. For!-arrestin
knockdown, monolayers (50% confluent) in 24 wells were
treated with 125 ng of siRNA/1.5 "l of HiPerFect 72 h before
the experiment.
Equilibrium Binding Experiments at 4 °C—The dissociation
constant (Kd) was determined with [3H]BK as described previ-
ously (24). In brief, cells were incubated for 90 min on ice in
incubation buffer (40 mM Pipes, 109 mM NaCl, 5 mM KCl, 0.1%
glucose, 0.05% BSA, 2mMCaCl2, 1mMMgCl2, pH 7.4) contain-
ing increasing concentrations of up to 30 nM [3H]BK. Surface-
bound [3H]BK ("95% of totally bound radioactivity) was disso-
ciated by a 10-min incubation with 0.2 ml of an ice-cold
dissociation solution (0.5 M NaCl, 0.2 M acetic acid, pH 2.7),
transferred to a scintillation vial, and counted in a !-counter
after the addition of scintillation fluid.
Determination of Inositol Phosphate (IP) Release—Phos-
phatidylinositol hydrolysis was measured as previously
described (24). In brief, confluent cell monolayers (24 wells)
were incubated overnight in 0.5 ml of complete medium con-
taining 1 "Ci [3H]inositol/ml. The cells were preincubated for
90 min on ice in incubation buffer supplemented with 50 mM
LiCl with or without the addition of increasing concentrations
of BK. Stimulation was started by placing the cells in a water
bath at 37 °C. After 30 min IP accumulation was stopped by
exchanging the medium for 1.5 ml of ice-cold 20 mM formic
acid solution. After 1 h on ice and application of the superna-
tant to AG 1-X8 columns, total [3H]IP was determined as
described before (24).
[3H]BK Internalization—Internalization of [3H]BK was
determined as described recently (24). Cells onmultiwell plates
(24/48 wells) were incubated with the indicated [3H]BK con-
centration in incubation buffer for 60min on ice to obtain equi-
librium binding. [3H]BK internalization was started by placing
the plates in a water bath at 37 °C for the indicated times and
stopped by putting them back on ice. Surface-bound [3H]BK
was dissociated by incubating the cells for 10 min with 0.2 M
acetic acid, 0.5 MNaCl, pH 2.7. Thereafter, internalized [3H]BK
was determined by lysing the cell monolayer with NaOH (0.3
M). [3H]BK in both samples was measured in a !-counter after
the addition of scintillation fluid. Internalization was expressed
as the amount of internalized [3H]BK in the percentage of the
combined amounts of internalized and surface-bound [3H]BK.
For the determination of intrinsic receptor internalization
properties (widely unaffected by high receptor expression
and/or limited availability of endogenously expressed interac-
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tion partners) we used [3H]BK concentrations !1 nM (25). To
detect endogenous factors that might limit the process (e.g.
"-arrestins) we used 5 nM or higher concentrations as
indicated.
Receptor Down-regulation—Monolayers (48-well) were
incubated with or without 1 #M unlabeled BK in 0.5ml of Opti-
MEM I for the indicated times at 37 °C. Thereafter, plates were
rinsed with ice-cold PBS and incubated on ice for 10 min with
0.2ml of dissociation solution to remove all unlabeled extracel-
lular ligand. The cells werewashed againwith ice-cold PBS, and
specific binding was determined with 2 nM [3H]BK at 4 °C by
subtracting nonspecific binding (determined in the presence of
5 #M unlabeled BK) from total surface binding.
Co-immunoprecipitation—Confluent monolayers of cells
stably expressing HA-tagged receptor constructs on 10-cm
dishes were transfected with 5 #g of plasmid harboring the
respective constructs and 10 #l of EcoTransfect 36 h before
co-immunoprecipitation. Cells were washed twice with PBS,
warmed up to 37 °C in a water bath, and subsequently stimu-
lated with 1#MBK for the indicated times in 4.8ml of PBS. The
stimulation was stopped by the addition of 0.2 ml of 25 mM
cross-linking agent (DSP, dissolved in DMSO) to obtain 1 mM
final concentration. After incubation for 20 min at room tem-
perature, cells were rinsed 3 times with quenching solution (50
mM Tris-HCl, pH 7.4) and solubilized in 1 ml of lysis buffer (10
mMTris-HCl, 25mMKCl, 150mMNaCl, 0.1%TritonX-100, pH
7.4) including protease inhibitors for 15 min at 4 °C with gentle
agitation. After centrifugation at 17000 ! g for 15 min at 4 °C,
20#l of the supernatant wasmixedwith an equal amount of 2!
LDS sample buffer containing 0.2 M DTT and incubated for 10
min at 95 °C; the residual supernatant was added to 20 #l of
EZview red anti-HA affinity gel and incubated for 1 h under
gentle agitation at 4 °C. Thereafter, the anti-HA matrix was
washed 3 times with ice-cold lysis buffer, then 30 #l of 1! LDS
sample buffer containing 0.1 M DTTwas added, and the immu-
nocomplexes were dissociated at 95 °C for 10 min. Samples
were separated on a 4–12% SDS-polyacrylamide gel and trans-
ferred to a 0.45-#m nitrocellulose membrane, which was
blocked for 1 h at room temperature with milk powder dis-
solved in TBST (Tris-buffered saline, pH 7.5, 0.1% Tween 20).
Subsequently the membrane was incubated overnight at 4 °C
with anti-"-arrestin2 antibody (1:1000) or for 1 h at room tem-
perature with anti-"-arrestin1- or anti-GRK3 antibody, each
diluted 1:1000 in blocking buffer. Thereafter, the membrane
was washed with TBST and incubated with HRP-linked goat
anti-rabbit IgG diluted 1:2000 in blocking solution. For the rec-
ognition of the primary mouse anti-"-arrestin1 antibody, the
peroxidase-labeled anti-mouse true blot secondary antibody
(1:2000) (eBioscience, San Diego, CA) was used. Antibody
binding was detected using ECL solution according to the
instructions of the manufacturer.
Immunoblotting—Confluentmonolayers in 6-well trayswere
washed 3 times with ice-cold PBS and solubilized in 300 #l of
lysis buffer and cleared by centrifugation as described above.
Aliquots of the supernatant were mixed with equal amounts of
2! LDS sample buffer (0.2 MDTT) and incubated for 10min at
95 °C, and proteins were electrophoresed, electroblotted, and
detected as described above. For deglycosylation, 5 #l of 10!
deglycosylation buffer (PBS, 20 mM EDTA, 1% SDS, 5% Triton
X-100, 10% 2-mercaptoethanol) was added to 45 #l of clear cell
lysate and denatured at 80 °C for 10min. After the addition of 1
unit of N-glycosidase F, the samples were incubated for 2 h at
37 °C without agitation and mixed with 1! LDS sample buffer
(0.1 M DTT). HA-tagged receptors were visualized after 1 h of
blocking in 5% milk powder at room temperature followed by
1 h of incubation with a monoclonal HRP-linked anti-HA high
affinity antibody (1:2000) diluted in fresh blocking buffer.
Surface Biotinylation—Cells stably expressing receptor con-
structs were plated on 6 well and incubated for 3 h at 37 °C in
Opti-MEM I containing ligand or vehicle. Subsequently, cells
were washed with ice-cold PBS and incubated on ice for 30min
with a solution of 0.3 mg/ml thiol-cleavable sulfo-NHS-SS-bi-
otin (Pierce) dissolved in PBS. After cell lysis, biotinylated
receptors were precipitated and run on a SDS-PAGE as
described above. Dissociation of precipitated receptors was
performed in DTT-free Laemmli buffer to avoid cleavage of the
biotin linker. After blotting, the receptors were detected with
the Vectastain ABC Kit (Vector Laboratories, Burlingame, CA)
according to the manufacturer’s instructions.
ERK1/2 Phosphorylation—Cells stably expressing GRKs 2–6
were plated on 24 wells and transfected with the B2RwtH. After
12 h the culture medium was changed for DMEM containing
reduced FCS (0.5%) and 0.5 #g/ml tetracycline to induce gene
expression. Another 36 h later the cells were washed with ice-
cold PBS and incubated on ice in 0.15-ml incubation buffer
containing 1#MBK. After 30min, the plates were put in a 37 °C
warmwater bath for the indicated times. Subsequently the cells
were solubilized in 0.2 ml of lysis buffer, and proteins were
separated by SDS-PAGE as described above. After electro-
blotting and blocking with 5%milk powder in TBST, phospho-
ERK1/2 and total-ERK1/2 were detected with phospho-p44/42
MAPK (E10) and a p44/42MAP kinase (3A7) mouse monoclo-
nal antibody (Cell Signaling, Frankfurt, Germany), respectively.
Epifluorescence Microscopy—Cells stably expressing eYFP-
receptor fusion proteins were seeded on glass coverslips. The
cell culture medium was changed to Opti-MEM I medium
before incubation with 1 #M BK or 1 #M JSM10292. Images
were taken with a Olympus IX70 fluorescence microscope.
Data Analysis—All experiments were performed at least
three times in duplicate or triplicate, and results are given as the
mean " S.E. unless otherwise indicated. Data analysis was car-
ried out using GraphPad Prism for Macintosh, Version 4.0c
(GraphPad Software, Inc.).
RESULTS
Helix 8 Requirement for High B2R Cell Surface Expression—
To investigate the importance of helix 8 for the function of the
B2R, we generated several constructs with increased trunca-
tions of the C terminus up to the center of helix 8 (Fig. 1A).
Moreover, to disturb the structure of helix 8 by a single point
mutation, leaving the B2RC terminus otherwise unchanged, we
mutated Lys-315, located in the center of helix 8, to proline
(construct K315P), a knownhelix breaker (Fig. 1A). As a control
that altered properties observed in K315P are not caused by
Lys-315 being an important residue per se, e.g. as a target for
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ubiquitination or for the overall receptor structure, mutant
K315A was generated as well.
Employing the Flp-In system (Invitrogen), all N-terminally
HA-tagged receptor constructs became stably integrated at an
identical unique locus in the genome of the HEK 293 host cell
line under the control of the strong cytomegalovirus (CMV)
promoter. Construct G327* (G327stop), displayed with about
18 pmol!mg!1 protein!1 similar maximal surface receptor
numbers (Bmax) as the wild-type B2R (B2Rwt) (Fig. 1B, Table 1).
However, truncations of the C terminus proximal to Cys-324
resulted in progressively reduced surface expression down to
2–3 pmol!mg!1 protein!1. Lower surface receptor numbers
were also observed for mutant K315P (5.3 pmol!mg!1 protein)
but not for mutant K315A ("16 pmol!mg!1 protein) (Fig. 1B;
Table 1). These results demonstrate that the distal C terminus
of theB2R is not required for high surface expression but that an
intact helix 8 contributes to it as being reported for other
GPCRs (11, 16, 17, 26). To be able to directly compare the prop-
erties of the different constructs without having to consider the
potential influence of the highly different surface expression
levels, we also generated cell lines, where the normally highly
expressed constructs (B2Rwt, G327*, G322*, K315A) were
expressed at distinctly lower levels under the control of the
weaker Pmin promoter (Fig. 1B; Table 1, constructs were
denoted with inferior L or H for low and high expression,
respectively). These distinctly lower surface expression levels
were similar to those determined for mutants, which exhibit
low levels despite being under the control of the strong CMV
promoter, i.e. constructs Y320*, V319*, and K315P.
Immunoblot analysis of the expressed constructs using the
N-terminal HA tag revealed several bands between 45 and 75
kDa as well as prominent double bands below 40 kDa (Fig. 1C,
upper panel). All truncations made proximal to Cys-324
(G322*, Y320*, Y319*) displayed a weaker pattern of bands
between 40 and 75 kDa but very strong double bands. Pretreat-
ment of protein lysates with N-glycosidase F resulted for all
samples in the appearance of one additional major lower band
and more intense double bands (Fig. 1C, lower panel), demon-
strating that the different bands reflect different glycosylation
states and that also the double bands represent intact receptor
protein and not degradation products. These results point to a
role of helix 8 in the B2R in stabilizing a proper conformation
that allows for full glycosylation and efficient trafficking to the
plasma membrane.
Reduced G Protein Activation of Helix 8 Mutants—To deter-
mine the participation of helix 8 in G protein activation, we
measured the accumulation of total IPs in the respective cell
lines after stimulation with increasing concentrations of BK for
30 min at 37 °C. Mutant G327*, lacking the whole C terminus,
exhibited an almost 30-fold lower EC50 value than B2Rwt and
also elevated levels ("2–3-fold as compared with B2Rwt) of
basal IP accumulation (Fig. 2; Table 1).
FIGURE 1. B2R constructs and their expression levels in HEK 293 cells. A, shown is a schematic representation of the C-terminal amino acid sequences of the
human B2Rwt and the mutant receptor constructs. Alignment starts after the conserved NPXXY motif after transmembrane helix 7. The predicted helix 8 is
framed, and the point mutations (K315P, K315A) are bold and underlined; the C-terminal serine/threonine phosphorylation sites are in bold. B, maximal
numbers of binding sites were determined with 30 nM [3H]BK. Open columns, expression of constructs under the control of the CMV promoter; filled columns,
expression of constructs under the weaker Pmin promoter. C, cells stably expressing HA-tagged B2Rwt and mutants (inferior H and L for high and low
expression) were lysed and separated by SDS-PAGE followed by Western blotting and detection with a monoclonal HA-antibody (upper panel). Aliquots of the
same lysates were incubated with 1 units of N-glycosidase F as described under “Experimental Procedures” but otherwise treated identically (lower panel). 5 !g
protein was applied for constructs marked in bold, and 15 !g of protein was applied for the remaining constructs. Numbers on the left represent relative
molecular masses (in kDa).
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In contrast, all mutants with a defective helix 8 (including
K315P) displayed !3–8-fold lower G protein-coupling effi-
ciencies, whereas the maximal responses were comparable for
all constructs (Fig. 2; Table 1). Mutant K315A behaved very
much likeB2Rwt,demonstrating that apositive charge in thisposi-
tion is not required forGprotein activation. Together, allmutants
showed robust phosphatidylinositol hydrolysis, indicating that the
overall receptor structure is largely unaffected by the mutations.
But helix 8 must directly or indirectly participate in the G protein
activation of the B2R as the EC50 values of the helix 8-defective
mutants clearly differed from that of B2Rwt.
Requirement of an Intact Helix 8 for B2R-mediated [3H]BK
Internalization—After stimulation with BK, the B2R becomes
rapidly sequestered to compartments within the cell. To inves-
tigate the role of helix 8 for receptor sequestration, we exam-
ined the capability of the receptor constructs to internalize
[3H]BK. As a consequence of the lacking C terminus, construct
G327* displayed strongly reduced internalization of 3[H]BK as
compared with the B2Rwt (Fig. 3A). Mutants with a disturbed
helix 8 were not capable of internalizing [3H]BK at all, whereas
construct K315A behaved like B2Rwt. These results show that
lack of the receptor C terminus with the phosphorylation sites
only reduces rapid receptor sequestration, whereas a defective
helix 8 prevents it almost completely as best demonstratedwith
K315P, a construct still comprising the complete C terminus
with all phosphorylation sites (Fig. 3A).
TABLE 1
[3H]BK binding data and BK-induced IP accumulation
Number of experiments are given in parentheses. ND, not determined. Significance was determined by one-way ANOVA using Dunnett‘s multiple comparison test.
*, position of the stop codon in each truncated receptor.
Receptor constructa
[3H]BK binding IP accumulation
Bmaxb Kd (4°) Basalc Maximal effectc EC50d
pmol/mg protein nM nm
B2RwtH 15.1 " 0.7 (6) 2.90 " 0.32 (19) 2.02 " 0.13 (10) 12.55 " 1.00 0.83 " 0.22 (6)
B2RwtL 4.5 " 0.4 (6)
K315PH 5.3 " 0.4 (6) 6.61 " 0.58 (5) 1.78 " 0.16 (4) 8.28 " 0.02 5.96 " 0.73 (4)e
K315AH 15.6 " 1.1 (3) 7.14 " 1.35 (4) 2.28 " 0.17 (3) 9.66 " 1.52 0.28 " 0.07 (3)
K315AL 3.6 " 0.4 (3)
G327*H 17.9 " 0.7 (3) 4.83 " 0.84 (9) 8.81 " 1.60 (4) 13.58 " 1.22 0.03 " 0.01 (5)
G327*L 3.3 " 0.4 (3)
G322*H 7.4 " 0.3 (3) 3.42 " 0.73 (5) ND ND ND
G322*L 1.4 " 0.1 (3)
Y320*H 1.7 " 0.2 (6) 2.63 " 0.52 (9) 1.61 " 0.31 (6) 11.08 " 1.48 2.27 " 0.95 (3)
V319*H 2.6 " 0.2 (6) 2.99 " 0.70 (7) 1.64 " 0.08 (7) 7.75 " 0.89 6.01 " 1.26 (4)e
K315*H 3.2 " 0.4 (3) 3.79 " 0.22 (3) 1.67 " 0.16 (3) 9.39 " 1.08 10.63 " 1.54 (4)e
R313*H 2.7 " 0.2 (3) 6.51 " 1.13 (3) 1.78 " 0.09 (3) 3.98 " 0.13 ND
a Receptor constructs were isogenically and stably expressed under the control of the strong CMV promoter or the weaker Pmin promoter. Expression levels are indicated
with inferior H for high and L for low.
b Estimated with 30 nM [3H]BK on ice.
c Total IP accumulation after 30 min of incubation in buffer with inhibitors and 50 mM LiCl at 37 °C without (basal) and with (maximal effect) 1 !M BK, expressed as the -fold
increase of initial total IP content (t # 0 min).
d Calculated from incubations in duplicates with 10$12–10$5 M BK for 30 min at 37 °C in the presence of 50 mM LiCl.
e p % 0.01.
FIGURE 2. Dose-dependent IP release. HEK 293 cells stably expressing B2Rwt
or the mutants were stimulated with the indicated concentrations of BK for 30
min at 37 °C. Total inositol phosphate accumulations are shown as represent-
ative sigmoidal dose-response curves, normalized for maximal response
(100%).
FIGURE 3. [3H]BK internalization and long term down-regulation. A, HEK
293 cells stably expressing B2Rwt and the shown constructs were preincu-
bated with 1 nM [3H]BK for 60 min on ice and subsequently warmed up to
37 °C to start internalization. At the indicated times surface-bound and inter-
nalized [3H]BK were determined as described under “Experimental Proce-
dures.” Internalization is given as a percentage of total bound [3H]BK (surface
plus internalized [3H]BK). B, HEK 293 cells expressing B2Rwt or mutants were
incubated in the presence of 1 !M BK at 37 °C for the indicated times. Subse-
quently cells were treated with NaCl/acetic acid solution to remove all unla-
beled agonist. Remaining surface binding was determined with 2 nM [3H]BK at
4 °C and is given in a percentage of control (not treated with BK). Constructs
denoted with an inferior L (for low expression) were expressed under the
control of the Pmin promoter.
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Requirement of an Intact Helix 8 for Sequestration upon Long
Term Stimulation—We next investigated how the mutations
affect the outcome of long term stimulation by treating the cells
with a saturating concentration of BK (1 !M) for up to 5 h at
37 °C. Remaining surface binding was determined with 2 nM
3[H]BK at 4 °C after removal of all unlabeled BK with NaCl/
acetic acid solution. As receptor sequestration is considerably
slowed down per se by high expression levels of constructs (25),
we used the stable cell lines expressing receptor genes under the
control of the weaker Pmin promoter when available. Cell sur-
face binding was reduced bymore than 80% after 30min for the
B2RwtL and remained at that level for at least 5 h (Fig. 3B). Even
though receptor numbers decreased strikingly slower for
G327*L than for B2RwtL, they reached a similarly low level after
5 h of BK treatment. The degree of receptor sequestration was
progressively reduced with shortening the C terminus and was
completely prevented in mutation V319*, indicating that an
intact helix 8 is crucial for the sequestration of the B2R. This
notion was strengthened by the result that mutant K315P also
showed no reduction of surface binding within the 5-h time
frame of stimulation with BK, whereas K315AL behaved like
B2RwtL.
Epifluorescence Microscopy with N-terminally eYFP-tagged
Constructs—To visualize the localization of selected receptor
variants without affecting the function of the C terminus, we
generated fusion proteinswith eYFP joined to theirN terminus.
To allow for proper extracellular expression, the eYFP
sequence was preceded by the signal sequence of the human
frizzled 4 receptor as otherwise the fusion proteins were
trapped inside the cell. The integrity of the fusion constructs
was confirmed by Western blot analysis (not shown). Epifluo-
rescencemicroscopy revealed a strongly dispersed intracellular
localization of eYFP-V319* (not shown here) and of eYFP-
K315P (Fig. 4E), whereas eYFP-B2Rwt (Fig. 4A) and eYFP-
G327* (Fig. 4C) were almost exclusively located at the plasma
membrane. In these latter two cell lines, a strong redistribution
of the receptors from the plasma membrane to intracellular
vesicles after BK treatment became obvious, which proceeded
more rapidly for B2Rwt (shown after 30 min, Fig. 4B) than for
G327* (shown after 120 min, Fig. 4D), in accordance with the
sequestration data given in Fig. 3B. The fusion constructs of
V319* and K315P did not display any recognizable redistribu-
tion even upon prolonged stimulation (up to 5 h; not shown
here). However, when these two constructs were treated for 3 h
with the small molecule B2R antagonist JSM10292 (27),3 they
were found predominantly at the cell surface (shown here only
for eYFP-K315P (Fig. 4F).
These results were confirmed by cell surface biotinylation
followed by immunoprecipitation. Whereas the number of
biotinylated cell surface receptors was strongly reduced for
B2Rwt and mutant G327* after a 3-h incubation with BK, no
change was observed for mutant K315P (Fig. 4H). However, for
the lattermutant a significant increasewas observed upon incu-
bation with JSM10292 for 3 h (Fig. 4, G andH). A 16-h incuba-
tion of mutant K315P with this antagonist resulted even in a
change to an immunoblot pattern that resembled that of the
B2Rwt (Fig. 4I). These results suggest that the said B2R antago-
nist can correct the trafficking to the plasma membrane, ham-
pered by the disturbed helix 8.
Together these results confirm that rapid receptor internal-
ization is dependent on the presence of the C terminus. Yet
slower sequestration can occur in a C terminus-independent
way as well. For both processes, however, an intact helix 8 is
crucial.
C-terminal-independent B2R Internalization Mediated by
"-Arrestin2—The ubiquitously expressed "-arrestins1 and -2
have been shown to target GPCRs to clathrin-coated pits
through their interaction with clathrin and the adapter protein
AP-2, thereby promoting receptor internalization (28, 29). Fur-
thermore, Simaan et al. (30) have reported that in COS7 cells
"-arrestin2 mediates B2R internalization. To investigate
whether C-terminal-dependent and -independent receptor
endocytosis have different requirements for "-arrestins, we
used siRNA technology to reduce the endogenous levels of
"-arrestin1 and -2 in HEK 293 cells (Fig. 5B).
Single knockdown of "-arrestin1 had no significant impact
on B2Rwt internalization (Fig. 5A). Knockdown of "-arrestin2
reduced receptor endocytosis by 40%, which could be further
significantly decreased by an additional "-arrestin1 knock-
down, indicating a partly compensatory effect of "-arrestin1 in
the case of diminished "-arrestin2 levels (Fig. 5A). The latter
effect did not turn significant with a second set of "-arrestin
siRNAs (supplemental Fig. S2A). Comparing the two different
sets of siRNAs for their ability to reduce overexpressed"-arres-
tin1 and -2 levels, the first set proved to bemuchmore efficient
than the second (supplemental Fig. S2B). This might explain
why the additional effect of "-arrestin1 was not observed with
the second siRNAset, as it can apparently be observed onlywith
a highly efficient "-arrestin2 siRNA.
Receptor internalization of stably transfected G327* in HEK
293 cellswasmonitored using 1nM [3H]BK for 15min, as higher
concentrations made receptor endocytosis hardly detectable
for that mutant. Only knockdown of "-arrestin2, but not of
"-arrestin1, significantly reduced internalization of G327* (Fig.
5A). Simultaneous knockdown of both "-arrestin isoforms
could not further lower receptor internalization, indicating a
subtype-specific role of "-arrestin2 for the C terminus-inde-
pendent internalization.
We next examined [3H]BK internalization of transiently
transfected B2Rwt inHEK293 cells, which stably overexpressed
"-arrestin1 or "-arrestin2 (Fig. 5D). Only minor enhancing
effects of "-arrestin2 but not of "-arrestin1 overexpression on
[3H]BK internalization of B2Rwt were observed (Fig. 5C). How-
ever, under certain circumstances "-arrestin1 can also play a
role in this process as "-arrestin1 overexpression was able to
rescue internalization that had been reduced by siRNA knock-
down of endogenous "-arrestin2 (Fig. 5C). In contrast, overex-
pression of both "-arrestin subtypes strongly enhanced ligand-
induced internalization of G327*, with "-arrestin2 exhibiting a
significantly larger impact (Fig. 5C).
To directly assess the interaction of"-arrestinswith receptor
constructs, we performed co-immunoprecipitation with the
chemical cross-linker DSP using cells stably overexpressing
3 A. Faussner, S. Schüssler, J. Feierler, M. Bermudez, J. Pfeifer, K. Schnatbaum,
T. Tradler, M. Jochum, G. Wolber, and C. Gibson, submitted for publication.
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B2RwtH or G327*H. Each cell line was transiently transfected
with either !-arrestin1 or !-arrestin2. Both arrestins could be
co-immunoprecipitated with the B2Rwt after 5 min of stimula-
tion (Fig. 5E). Mutant G327* still bound !-arrestin2, but not
!-arrestin1, upon BK treatment, albeit obviously to a lower
extent than the B2Rwt.
These results suggest that internalization of G327* and
B2Rwt is largelymediated by the action of!-arrestin2, although
!-arrestin1 is able to functionally compensate in part for !-ar-
restin2 under certain circumstances (e.g. such as overexpres-
sion of !-arrestin1 or after !-arrestin2 knockdown). Further-
more, the C terminus of the B2R is less important for the
interaction with !-arrestin2 than for coupling of !-arrestin1.
Regulation of B2R-induced ERK1/2 Activation by GRK2 and
GRK3—GRKs phosphorylate almost exclusively agonist-acti-
vated receptors, and consequently there must be molecular
determinants of the receptor that signal the agonist-bound sta-
tus to theGRKs.Wehypothesized that helix 8might function as
such a signaling determinant. Overexpression of the ubiqui-
tously expressed GRKs 2–6 produced a different phosphoryla-
tion pattern of the B2R after stimulation (31); however, so far it
was not investigated whether this also results in different sig-
naling outcomes. Therefore, we first determined in our study
how overexpression of GRKs 2–6 in HEK 293 cells (supple-
mental Fig. S1A) affects ERK1/2 activation by the B2R. Of all
here-examined GRKs, only overexpression of GRK2 and -3 sig-
FIGURE 4. Cellular distribution of B2Rwt, G327*, and K315P. A–F, HEK 293 cells stably expressing eYFP-B2Rwt or eYFP-G327* were incubated at 37 °C in the
absence (NT) or presence of 1 "M BK for 30 min (eYFP-B2Rwt) or 120 min (eYFP-G327*). Mutant eYFP-K315P was treated 3 h with the small molecule antagonist
JSM10292. The eYFP fusion constructs were visualized by fluorescence microscopy. G, surface expression levels of receptor proteins were determined with a
membrane-impermeable biotinylated linker before (NT) and after 3 h of treatment of BK or JSM10292 as described under “Experimental Procedures.” H, shown
is quantification of biotin-reactive bands using Image J software. Receptor density is given as the mean ! S.E. of four different experiments in percentage of the
non-treated control. Significance was determined by one-way ANOVA using Bonferroni’s multiple comparison test. ***, p " 0.001. I, shown is a representative
immunoblot of K315P (#15 "g protein) treated without or with JSM10292 for 16 h
.
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nificantly reduced the ERK1/2 signal during the determination
period of 30 min (supplemental Fig. S1, B and C).
Promotion of Phosphorylation-independent Internalization
by GRK3—As GRK3 displayed the strongest effect, we chose
this kinase to investigate the importance of helix 8 for the inter-
action of the B2RwithGRKs. Stimulationwith BK resulted after
2 min in a stable interaction of GRK3 with the B2Rwt as well as
with G327*, which lasted for at least 30 min (Fig. 6A). Hence,
GRK3 interaction can occur independently of the C terminus,
its substrate, raising the question of whether there are other
functions of GRKs besides the mere phosphorylation of the
receptor C terminus. Overexpression of GRK2 or -3 resulted in
minor, but significant increases in the internalization of the
B2Rwt (not shown). However, also the internalization of G327*
(lacking the C terminus with all the phosphorylation sites) was
significantly increased by overexpression of GRK3 (Fig. 6B).
It has been shown that GRKs contain consensus clathrin-
binding motifs through which they are able to promote recep-
tor internalization (32, 33). To discriminate whether clathrin
binding and/or kinase activity promotes internalization of
G327*, we generated a GRK3 variant with a group mutation of
the clathrin binding motif to alanines (498LLDCD502 3
498AAAAA502; GRK3-5A) in addition to a kinase activity-defi-
cient mutant GRK3-K220R (Fig. 6C). Overexpression of
GRK3-5A or GRK3-K220R did not increase significantly the
internalization of G327* (Fig. 6B). Thus, the capability of GRK3
to promote B2R endocytosis independently of the C-terminal
phosphorylation sites still requires its kinase activity and the
simultaneous presence of the clathrin binding motif.
Requirement of the Receptor C Terminus for Rescue of K315P
Internalization by GRK3 and !-Arrestin2—Next, we investi-
gated whether overexpression of GRK3 and !-arrestin1 or -2
FIGURE 5. Subtype-specific role of !-arrestin2 for the internalization of B2Rwt and G327*. A, HEK 293 cells stably expressing B2Rwt or G327* were
transfected with the indicated siRNAs. 72 h later internalization was determined with 5 nM [3H]BK (B2Rwt) or 1 nM [
3H]BK (G327*) after 5 min (B2Rwt) or 15 min
(B2Rwt) as described under “Experimental Procedures.” B, shown is a representative immunoblot of endogenous !-arrestin levels in HEK 293 cells silenced with
the indicated siRNAs and probed with a monoclonal !-arrestin1 antibody recognizing both subtypes. C, HEK 293 cells stably expressing !-arrestin1 or
!-arrestin2 were transfected with B2Rwt or G327*, and internalization was determined after 48 h with 5 nM [
3H]BK (B2Rwt) or 1 nM [
3H]BK (G327*) after 5 min
(B2Rwt) or 15 min (G327*) at 37 °C. Where indicated, cells were pretreated with !-arrestin2 siRNA. D, shown is a representative immunoblot of cell lysates using
!2 "g of protein of cells overexpressing !-arrestin1 and -2. Statistical analysis was done with one-way ANOVA using Bonferroni’s multiple comparison test. ***,
p " 0.001, **, p " 0.01; *, p " 0.05. ctl, control. E, HEK 293 cells stably expressing HA-tagged B2RwtH or G327*H were transiently transfected with !-arrestin1 (left)
or !-arrestin2 (right) and stimulated (or not) with 1 "M BK for 5 min at 37 °C. After cross-linking with DSP and cell lysis, the protein complexes were precipitated
with anti-HA-matrix. Precipitates were separated by reducing SDS-PAGE, transferred onto nitrocellulose membranes, and probed for !-arrestin1 (left) or
!-arrestin2 (right) (top panels). Blots were stripped and re-probed to confirm receptor expression (middle panels), and lysates were tested for !-arrestin
expression (bottom panels). IP, immunoprecipitation; IB, immunoblot.
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would be able to rescue the internalization of mutant K315P,
which had a disturbed helix 8 but otherwise an intact C termi-
nus. Overexpression of GRK3 resulted in a strong increase of
ligand-induced internalization of K315P more than 2-fold,
whereas that of the kinase-dead mutant GRK3-K220R did not,
indicating the requirement of phosphorylation for the internal-
ization process (Fig. 6D). Internalization of K315P could also be
rescued by!-arrestin overexpression independently of the sub-
type, albeit to a smaller extent as compared with GRK3 (Fig.
6D). In contrast, in HEK 293 cells expressing the receptor
mutant K315P-G327* (which combined the defective helix 8
with the lack of the distal C terminus) neither overexpression of
!-arrestins nor GRK3 could significantly re-induce internaliza-
tion (Fig. 6E), suggesting that the rescue byGRK3or!-arrestins
is strongly dependent on the presence of the intact C terminus
or an intact helix 8.
Requirement of a SpecificMicroenvironment for Proper Func-
tion of Helix 8—Finally, to test whether C-terminal sequences
and/or helices 8 of different GPCRs of family A are functionally
transferable to the B2R, we generated various chimeras of the
B2R with the C termini/helices 8 of the protease-activated
receptor-2, the !2-adrenergic receptor, the angiotensin II type
1 receptor, and the B1 bradykinin receptor. Except B1 brady-
kinin receptor, all these receptors become phosphorylated and
internalized after agonist stimulation (34–37).
All chimeric constructs (Fig. 7A) were robustly expressed on
the cell surface (!5–10 pmol!mg"1protein"1) as determined
by radioligand binding assays with [3H]BK. The chimeras with
FIGURE 6. C terminus-independent GRK interaction and rescue of K315P internalization. A, HEK 293 cells stably expressing HA-tagged B2Rwt or G327*
were transiently transfected with GRK3 and stimulated (or not) with 1 "M BK for 2 or 30 min at 37 °C. After cross-linking with DSP and cell lysis, the protein
complexes were precipitated with anti-HA matrix. Precipitates were separated by reducing SDS-PAGE, transferred onto nitrocellulose membranes, and probed
for GRK3 (top panel). Blots were stripped and re-probed to confirm receptor expression (middle panel), and lysates were probed for GRK expression (bottom
panel). IP, immunoprecipitation; IB, immunoblot. B, cells stably expressing GRK3wt, GRK3-5A, or GRK3-K220R were transiently transfected with G327*, and
internalization was monitored with 1 nM [3H]BK for 15 min at 37 °C. Significance was determined by one-way ANOVA using Bonferroni’s multiple comparison
test. ***, p # 0.001. C, a representative immunoblot of cell lysates using !2 "g protein of cells (over)expressing GRK3wt, GRK3-K220R, and GRK3-5A is shown.
D and E, HEK 293 cells stably (over)expressing the indicated !-arrestin subtypes or GRK3 constructs were transiently transfected with either K315P or K315P-
G327*. Internalization was monitored for 15 min at 37 °C with 1 nM 3H. Significance was determined by one-way ANOVA using Bonferroni’s multiple compar-
ison test. ***, p # 0.001
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transfer of the C termini distal to helix 8 (B2CPAR2, B2CADR2,
B2CB1) showed strong phosphatidylinositol hydrolysis (Fig.
7B). For the other chimeras with transfer of helix 8 either with
or without the distal C terminus phosphatidylinositol hydroly-
sis apparently depended on the source of helix 8. When helix 8
was derived from another G protein Gq/11-coupledGPCR (pro-
tease-activated receptor-2, angiotensin II type 1 receptor), the
chimeras displayed robust signaling, whereas there was no sig-
naling when helix 8 was taken from the !2ADR (constructs
B2YADR2, B2YADR2CB2) that couples to G protein Gs.
Determination of receptor internalization showed a fast
uptake of [3H]BK in all chimeras with C terminus exchanges
distal of helix 8 (Fig. 7C). Solely, when the C terminus was
derived from the non-internalizing B1 bradykinin receptor
(construct B2CB1), a quite slow and low uptake was observed.
When helix 8 was substituted in addition, only the angiotensin
II type 1 receptor chimera was able to function like the B2Rwt,
whereas the other chimeras displayed hardly any [3H]BK up-
take at all.
Taken together, these results indicate that G protein activa-
tion might require only a helix 8 of a “donor” receptor that
couples to the same G protein, whereas with regard to receptor
internalization the structural requirements aremuchmore spe-
cific for a helix 8 to function properly in a different receptor
environment. In contrast, the C terminus distal to helix 8 can
apparently function to a great extent independently from the
receptor core in the internalization process.
DISCUSSION
Helix 8 and Surface Expression—The existence of an intra-
cellularly located 8th helix has been predicted for some GPCRs
(for review, see Ref. 38) and then confirmed with the resolution
of the first structure of a GPCR, the inactive rhodopsin (6). All
the following structures also displayed this helix 8 (8) with the
exception of CXCR4 (7). One reason for this high conservation
seems to be an important role of helix 8 in stabilizing the recep-
tor in a conformation that supports trafficking to the plasma
membrane. In this respect it has been reported for several
GPCRs that truncation of the C terminus up into the region of
helix 8 results in a strong loss of receptor surface expression (11,
16, 17, 26). Our results with the receptor chimeras and in par-
ticular with the helix 8 point mutant K315P of the B2R suggest
that for the presumably stabilizing effect of helix 8, its specific
amino acid composition is less important than maintaining its
overall helical structure; all our chimeric constructs with com-
plete transfers of helix 8 from one receptor to another were
robustly expressed, but disturbance of helix 8 in the B2R (point
mutant K315P) resulted in much lower surface binding than
observed for the B2RwtH accompanied by strong intracellular
localization (Fig. 4E).
As published recently, for the leukotriene B4 type 2 receptor
an intact helix 8 is required for the receptor to pass the quality
control process in the endoplasmic reticulum (17). In line with
this report,Western blot analysis of our constructs showed that
most of the newly synthesized helix 8-defective receptor pro-
teins are apparently insufficiently glycosylated and trapped
inside the cell. The observation that the helix 8-truncated con-
struct V319* as well as construct K315P reached the surface
when a membrane-permeable antagonist was added (Fig. 4F)
suggests that the receptor molecule in the absence of a func-
tional helix 8 can be stabilized by other means, e.g. an appropri-
ate antagonist. A similar pharmacological chaperone effect was
also reported for helix 8-defective mutants of the leukotriene
B4 type 2 receptor (17) and for themuscarinicM1 receptor (14),
implying a potential therapeutic approach to rescue respective
defective receptors.
Helix 8 andGProtein Activation—Structural data and exper-
imental approaches suggested that after binding an agonist on
the extracellular site, helix 8 might be one of the key elements
FIGURE 7. Internalization and signaling of chimeric constructs. A, alignment of the C-terminal residues of the human B2Rwt swapped with sequences of
various other GPCRs (marked in bold). Sequences were exchanged directly after the NPXXY motif of transmembrane helix 7 or after the proximal Cys-324,
respectively. The predicted helix 8 is framed. B, inositol phosphate release of B2Rwt and chimeras, stably expressed in HEK 293 cells, was determined with 1 "M
BK as described under “Experimental Procedures.” The results are presented as -fold increase over the IP content of identically treated control cells that had
remained on ice. C, internalization of B2Rwt and chimeras stably expressed in HEK 293 cells was determined as described under “Experimental Procedures.”
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for transferring the information into the cell through becoming
accessible for recruitment and activation of intracellular signal-
ing proteins (9, 39, 40). There is now substantial experimental
evidence for the involvement of helix 8 (11–13, 41–44) in the
process of G protein activation, e.g. for several GPCRs it has
been reported that truncation or deletion of helix 8 results in
reduced activation (11–13, 44). Moreover, earlier studies have
demonstrated that peptides derived from the helix 8 of rhodop-
sin (41) or the angiotensin II receptor (42, 43) can directly inter-
act with the respective G proteins. It has also recently been
reported that themodified C terminus of the G protein subunit
Gq can be cross-linked to several helix 8 residues of the musca-
rinicM3 receptor (45). Pointing in the samedirection of a direct
involvement of helix 8 in the interaction with theG proteins, all
our B2R mutants with a disturbed helix 8 displayed a distinct
increase in the EC50 values for phosphatidylinositol hydrolysis
as compared with the B2Rwt.
Helix 8 andB2R-GRK Interaction—Whereas the publications
so far have focused almost exclusively on a role of helix 8 in
receptor expression or in G protein activation, it was just
recently reported that helix 8 might also play a role in receptor
phosphorylation and, therefore, in the interaction with GRKs
(18).Mutation of basic residues in the helix 8 of the thyrotropin
releasing hormone receptor resulted in reduced receptor inter-
nalization and phosphorylation that could be rescued partly by
overexpression of GRK2 or -3 and fully by overexpression of
GRK5 or -6. We have shown here that disturbance of helix 8 in
the B2R by truncation or mutation of a central residue to a
proline (construct K315P) strongly diminished ligand-induced
receptor internalization. For K315P, this effect could in part be
overcome through overexpression of GRK3 (or GRK2, data not
shown here) but not of the kinase-inactive variant GRK3-
K220R (or of GRK5 or GRK6; data not shown). Therefore, we
suggest that helix 8 of the B2R participates directly or indirectly
in specific high affinity binding of GRK3 (or GRK2). Accord-
ingly, low affinity binding due to a defective helix 8 can be com-
pensated for by GRK3 overexpression, which presumably
results in normal phosphorylation of serine/threonine residues
in the B2R C terminus if present, thus rescuing receptor inter-
nalization. In agreement with this proposal, rescue by GRK3
was not possible for construct K315P-G327*, having a defective
helix 8 and lacking the C terminus (Fig. 6E). On the other hand,
the reduced internalization observed for the B2R truncation
G327*, caused by the absence of the receptor C terminus with
its phosphorylation sites, could also be partly rescued by over-
expression of GRK3 but only when GRK3 kinase activity was
left functional and when the GRK3 clathrin binding site was
preserved. Together with the data that mutant G327* ligand-
dependently binds GRK3 (Fig. 6A), our results support the idea
that receptor-bound GRK3 may also phosphorylation-inde-
pendently mediate directly internalization via clathrin-coated
pits.
Helix 8 and Arrestin Interaction—Our results show that the
presence of an intact helix 8 alone without the respective C
terminus is sufficient for the B2R to associate with !-arrestin2,
but not with !-arrestin1, and to generate robust internaliza-
tion, although to a distinctly lesser extent than observed for the
B2Rwt. The combination of a disturbed helix 8 with C-terminal
truncation (mutantK315P-G327*) completely abrogates recep-
tor endocytosis and prevents even any rescue attempts by over-
expression of !-arrestins. These data indicate that helix 8 is
crucial to preferably recruit !-arrestin2 to the activated recep-
tor and that preceding phosphorylation of the B2R C terminus
might ensure high affinity !-arrestin2 binding but is not abso-
lutely required for a productive interaction. In contrast, !-ar-
restin1 is likewise strictly dependent on the B2R C terminus, as
it does not associate notably with construct G327*, at least not
under the conditions applied (Fig. 5E). However, it may substi-
tute for !-arrestin2 in the sequestration of the B2R and even of
G327* when !-arrestin2 levels are markedly reduced (siRNA
knockdown) or with !-arrestin1 being strongly overexpressed
(Fig. 5C). Our observed subtype-specific differences are in good
agreement with a report by Zhang et al. (46, 47), who have
previously shown that the phosphorylation-independent inter-
nalization of the "-opioid receptor is regulated via !-arrestin2,
but not via !-arrestin 1, which exclusively promotes the phos-
phorylation-dependent internalization.
Conclusions—Our data support the following models for the
activation of the B2R. Subsequent to an agonist-induced change
in the overall receptor conformation, helix 8 becomes accessi-
ble as an interaction site not only for G proteins but also for
GRK2/3 and for !-arrestin2, yet less for !-arrestin1. With
regard to receptor internalization of the B2R, helix 8 is appar-
ently more important than the remaining C terminus with its
phosphorylation sites, as ligand-induced receptor internaliza-
tion was still functional in the absence of the C terminus but
completely abrogated when helix 8 was disturbed by a proline
point mutation. Alternatively, helix 8 does not function as a
direct interaction site for G proteins, GRKs, or arrestins but
indirectly as a key player in stabilizing receptor conformations
that result in these interactions after binding of an agonist.
Finally, recent reports have shown that helix 8 can serve as an
allosteric binding site for small molecule compounds (48, 49).
Given the fact that the various functions of GPCRs are differ-
entially affected by manipulations of helix 8, as demonstrated
by our group and other researchers, targeting helix 8 as an allos-
teric regulatory binding site appears to be an interesting
approach in the quest for more specific GPCR-related drugs.
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Alanine screening of the intracellular loops of the human
bradykinin B2 receptor – effects on receptor maintenance,
G protein activation and internalization
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The human bradykinin B2 receptor (B2R) mediates the
effects of the nonapeptide bradykinin (BK) and of kal-
lidin (lysyl-BK). B2R has been reported to play a role
in a number of physiological and pathophysiological
situations. Its activation causes vasodilation and hypo-
tension, increased vascular permeability and edema, or
generation of pain via C fibers [1]. B2R, which is
expressed constitutively in many tissues and cultured
cells, is a prototypical member of family A (rhodopsin ⁄
b-adrenergic-like receptors) of the membrane-bound
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The bradykinin B2 receptor is coupled to G protein Gq ⁄ 11 and becomes
sequestered into intracellular compartments after activation. To more clo-
sely define the receptor sequences involved in these processes and their
functions, we systematically mutated all three intracellular loops (ICLs),
either as point mutations or in groups of three to five amino acids to Ala,
obtaining a total of 14 mutants. All constructs were stably expressed in
HEK 293 cells and, with the exception of triple mutant DRY fi AAA,
retained the ability to specifically bind [3H]bradykinin. The binding affini-
ties at 4 or 37 !C of several mutants differed considerably from those deter-
mined for the wild-type receptor, indicating an allosteric connection
between the conformation of the binding site and that of the ICLs. Muta-
tions in ICL-1 strongly reduced surface expression without affecting G pro-
tein signaling or [3H]bradykinin internalization. Two cluster mutants in the
middle of ICL-2 containing basic residues displayed considerably reduced
potencies, whereas two mutations in ICL-3 resulted in receptor conforma-
tions that were considered to be semi-active, based on the observation that
they responded with phosphoinositide hydrolysis to compounds normally
considered to be antagonists. This, and the fact that a cluster mutant at
the C-terminal end of ICL-3 was signaling incompetent, hint at the involve-
ment of ICL-2 and ICL-3 in Gq ⁄ 11 activation, albeit with different func-
tions. None of the mutants displayed reduced ligand-induced receptor
internalization, indicating that the loops are not essential for this process.
No conclusion could be drawn, however, with regard to the role of
the DRY sequence, as the corresponding triplet mutation lacked binding
capability.
Abbreviations
B2Rwt, bradykinin B2 receptor wild-type; BK, bradykinin; CMV, cytomegalovirus; EC50, half-maximal effective concentration; GPCR, G
protein-coupled receptor; GRK, G protein-coupled receptor kinase; HA, hemagglutinin; HEK 293, human embryonic kidney cells; ICL-1, ICL-2,
ICL-3, first, second and third intracellular loops; IP, inositol phosphate; PAO, phenylarsine oxide.
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G protein-coupled receptors (GPCRs), and has been
shown to be coupled preferably to G protein Gq ⁄ 11.
Following activation, the receptor is rapidly desensi-
tized by phosphorylation of Ser ⁄Thr residues in its
C-terminus via the actions of protein kinase C and ⁄or
G protein-coupled receptor kinases (GRKs) [2]. This
leads to recruitment of arrestins and sequestration of
the receptor either via clathrin-coated pits or caveolae
[3,4]. Which path is actually taken may depend on the
cell type and the receptor expression levels. Although
the processes of signaling and regulation of human
B2R are, in general, fairly well understood, the knowl-
edge of the molecular basis of these events at the struc-
tural level of the receptor is still very limited. For
example, it is not known which determinants in the
intracellular loops (ICLs) of the receptor are responsi-
ble for self-maintenance, for the recruitment and acti-
vation of the G protein, or for the initiation of the
desensitization process (i.e. for relaying the information
to GRKs and arrestins that the receptor is in an ago-
nist-bound state and therefore is a target or a potential
interaction partner). For other family A GPCRs, all
three ICLs have been shown to participate, in one way
or another, in either G protein activation or receptor
sequestration [5,6]. Basic and hydrophobic residues in
the second and third ICLs (ICL-2 and ICL-3, respec-
tively) of the muscarinic receptor were identified as
functionally important for G protein coupling [7,8].
ICL-1 and ICL-3 play a role in the interaction of the
d-opioid receptor with Ga16 [9]. A highly conserved
Pro ⁄Ala, found in ICL-2 of most family A GPCRs,
was demonstrated, by gain- and loss-of-function stud-
ies, to be a coupling site for arrestins [10]. Given that
this Pro is not conserved in B2R, however, other resi-
dues must play a role in the internalization process of
this receptor. For these reasons, we decided to system-
atically perform Ala screening of all three ICLs of the
human B2R in order to avoid any bias with regard to
which loops or residues might be crucial. This unbiased
approach was also based on the high degree of conser-
vation of B2R sequences in the ICLs among species,
which suggests structural or functional importance.
We mutated single amino acids, or clusters of three
to five amino acids, in all three ICLs to Ala and
expressed the resulting 14 mutants stably and isogeni-
cally (i.e. stable integration of the receptor genes at the
same unique gene locus) in HEK 293 (human embry-
onic kidney) cells. All clones were examined for recep-
tor self-maintenance (surface expression levels),
conformation of the binding site (equilibrium dissocia-
tion constants at 4 and 37 !C), signal transduction
[half-maximal effective concentration (EC50) and maxi-
mal effect of inositol phosphate (IP) accumulation]
and agonist-induced receptor internalization. Our
results indicate a different function for the loops in G
protein activation: stretches in ICL-2 seem to be
responsible for the binding of G protein Gq ⁄ 11 and, in
ICL-3, for keeping the receptor in an inactive state, i.e.
blocking ⁄ regulating the productive interaction with
Gq ⁄ 11. All expressed mutants were sequestered rapidly
after activation, suggesting little or no involvement of
the loops in the interaction with arrestins or kinases.
One possible interaction site with arrestins remains,
however, as mutation of the DRY sequence to triple
Ala resulted in a complete loss of surface binding
activity, preventing any further investigation.
Results
Ala scanning of the ICLs of B2R
In order to identify single residues or sequences in the
ICLs of human B2R that play a role in receptor signal-
ing and regulation, we made systematic substitutions
of amino acids for Ala, either as point mutations or in
clusters of three to five residues, as indicated in Fig. 1.
In the first loop (ICL-1), two group mutations (termed
constructs 1 ⁄ 1 and 1 ⁄ 2) and one point mutation
(E66A) were made. In the second loop (ICL-2), five
group mutations (termed constructs 2 ⁄ 1–2 ⁄ 5) were
produced. In the third loop (ICL-3), five group muta-
tions (termed constructs 3 ⁄ 1–3 ⁄ 5) and one point muta-
tion (T242A) located at the C-terminal end were
generated. The amino acids mutated to Ala are listed
in Table 1 and their numbering is given in Fig. 2A. In
accordance with Hess et al. [11], sequence numbering
starts at the third encoded Met residue.
ICL-1 and sequences at the N-terminus of ICL-2
and at the C-terminus of ICL-3 are crucial for
receptor surface expression
All receptor constructs were stably and isogenically
expressed in HEK 293 cells. Employing the Flp-In sys-
tem (Invitrogen, Groningen, the Netherlands), the con-
structs become integrated at an identical unique locus
in the genome of the host cell. If this does not occur,
the cells acquire no resistance to the selection antibiotic
hygromycin. Despite their isogenic expression, the max-
imal receptor numbers (Bmax) of the various constructs
differed markedly, and several receptor mutants were
expressed at significantly lower levels than the wild-
type B2R (termed B2RwtH = 11.0 ± 0.7 pmolÆ(mg
protein))1], even though their expression was under the
control of the same cytomegalovirus (CMV) promoter
(Fig. 2A, Table 1). For this reason, we also used the
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Flp-In system with a weaker promoter (Pmin), consist-
ing of only the last 51 nucleotides of the CMV pro-
moter, to obtain a distinctly lower expression level
[2.4 ± 0.3 pmolÆ(mg protein))1] for B2Rwt (termed
B2RwtL). For this construct, expression was similar to
that achieved for the lower expressed mutants. B2RwtL
also served to estimate the degree to which the receptor
expression level might influence the parameters under
investigation. We have observed that compounds such
as icatibant and B9430, which are generally considered
to be antagonists, become partial agonists with high
B2Rwt expression levels (A. Faussner et al., unpub-
lished results), indicating that high over-expression
might generate some kind of artifact. To avoid this, we
additionally generated lower expressing cell lines under
the control of the Pmin promoter for some of the con-
structs in ICL-3 (Fig. 2A, filled bars) that otherwise,
with the CMV promoter, displayed very high expres-
sion levels (Fig. 2A, Table 1) and ‘antagonist-inducible’
signaling (not shown).
Table 1. [3H] binding data, and basal and BK-induced IP accumulation (NA, not applicable).
Receptor
construct
[3H]BK binding IP accumulation
Bmax
a [fmolÆ(mg
protein) )1]
Kd(PAO ⁄ 37 !C)
(nM)
Kd(PAO ⁄ 4 !C)
(nM)
Kd ratio
37 ⁄ 4 !C Basalb
Maximal
effectb EC50
c (nM)
B2RwtH 11.0 ± 0.7 10.42 ± 1.56(4) 2.81 ± 0.7 3.7 2.02 ± 0.13(8) 12.55 ± 1.00 0.79 ± 0.34(4)
B2RwtL 2.4 ± 0.3 8.05 ± 1.10(5) 2.02 ± 0.22 4.0 1.69 ± 0.09(4) 12.11 ± 1.22 0.67 ± 0.22(3)
1 ⁄ 1(CLHK) 2.3 ± 0.3 10.18 ± 0.21(3) 2.25 ± 0.37 4.5 1.76 ± 0.17(6) 14.18 ± 1.44 1.04 ± 0.21(5)
1 ⁄ 2(SSCT) 0.9 ± 0.1 3.21 ± 0.31(3) 0.79 ± 0.11 4.1 1.61 ± 0.05(4) 5.58 ± 0.09 0.43 ± 0.08(6)
E66A 0.7 ± 0.4 3.77 ± 0.67(3) 0.94 ± 0.29 4.0 1.81 ± 0.11(6) 6.77 ± 1.25 0.37 ± 0.07(3)
2 ⁄ 1(DRY) < 0.02 NA NA NA NA NA NA
2 ⁄ 2(LALV) 5.3 ± 0.2 2.96 ± 0.74(3) 1.80 ± 0.36 1.6 1.88 ± 0.13(5) 10.19 ± 1.50 2.96 ± 0.28(4)
2 ⁄ 3(KTMSM) 9.5 ± 0.7 9.22 ± 1.50(3) 2.80 ± 0.49 3.3 1.49 ± 0.07(3) 8.17 ± 0.72 11.66 ± 1.94(6)
2 ⁄ 4(GRMR) 10.2 ± 0.3 14.19 ± 1.36(3) 3.64 ± 0.17 3.9 1.40 ± 0.11(6) 9.90 ± 2.20 11.56 ± 3.02(5)
2 ⁄ 5(GVR) 10.3 ± 0.6 12.99 ± 0.78(4) 4.43 ± 0.57 2.9 1.59 ± 0.14(8) 14.46 ± 1.10 1.33 ± 0.22(5)
3 ⁄ 1(MQVLR) 5.0 ± 0.6 3.45 ± 0.53(5) 1.87 ± 0.45 1.8 1.72 ± 0.18(5) 6.91 ± 1.22 3.17 ± 0.45(3)
3 ⁄ 2(NNEMQ) 11.0 ± 1.3 9.54 ± 0.90(3) 5.37 ± 1.38 1.8 1.55 ± 0.12(5) 7.37 ± 0.86 3.12 ± 0.42(5)
3 ⁄ 3(KFK) 4.3 ± 0.7 7.93 ± 1.27(3) 2.18 ± 0.37 3.6 2.05 ± 0.17(4) 10.09 ± 1.14 3.78 ± 0.64(4)
3 ⁄ 4(EIQ) 13.7 ± 0.8 8.52 ± 1.74(4) 5.24 ± 1.07 1.6 1.87 ± 0.33(3) 10.53 ± 3.25 1.49 ± 0.18(4)
3 ⁄ 5(TERR) 0.7 ± 0.0 1.63 ± 0.50(3) 0.86 ± 0.29 1.9 1.54 ± 0.16(5) 2.07 ± 0.38 NA
T242A 12.7 ± 0.6 6.70 ± 0.93(3) 3.38 ± 0.60 2.0 1.93 ± 0.07(3) 11.37 ± 0.72 0.97 ± 0.27(4)
a Estimated from at least three different clones in 24 wells after incubation with 200 lL of 30 nM [3H]BK on ice. b Total IP accumulation after
30 min of incubation in buffer with inhibitors and 50 mM LiCl at 37 !C with (maximal effect) and without (basal) 1 lM BK, expressed as the
fold increase of initial total IP production (t = 0 min). The results represent the mean ± SEM of the number of experiments (given in paren-
theses) performed in triplicate. c Calculated from incubations in duplicate with 10)12–10)5 M BK for 30 min at 37 !C in the presence of
50 mM LiCl. Results are the mean ± SEM of independent experiments (number indicated in parentheses).
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Of the constructs with Ala substitution in the
sequence of ICL-1, cluster mutant 1 ⁄2 and point
mutant E66A displayed particularly low binding activ-
ity, with less than 7% of that obtained for B2RwtH
(Fig. 2A). Exchange of the highly conserved DRY
sequence located at the transition of the cytosolic
extension of helix III and the N-terminus of ICL-2 for
three Ala residues resulted in a construct that did not
bind ligand. Figure 2B shows the immunoblot of hem-
agglutinin (HA)-tagged mutant 2 ⁄ 1 in comparison with
those of B2RwtH and B2RwtL. For both wild-type cell
lines, several bands were detected between 50 and
65 kDa with densities that largely reflected their rela-
tive expression levels, and two weaker bands at 42 and
39 kDa. Mutant 2 ⁄ 1, in contrast, displayed only strong
bands at 42 and 39 kDa and two weaker ones at 36
and 33 kDa. An unusual migration behavior has been
reported for B2R in SDS–PAGE [12,13]. Nevertheless,
the possibility remained that a lack of glycosylation
caused the major bands of mutant 2 ⁄ 1 to run at, or
below, the masses calculated for the B2R amino acid
sequence (approximately 40 kDa). However, as
observed for both the high- and low-expressed B2R
wild-types, the bands of mutant 2 ⁄ 1 still displayed a
clear shift to lower masses after enzymatic deglycosyla-
tion treatment (Fig. 2B). After deglycosylation, the
major bands of construct 2 ⁄1 corresponded to the
mass of the N-glycosylation-deficient mutant
N3 ⁄ 12 ⁄ 180H. These results suggest that this receptor
mutant is expressed and glycosylated, but nevertheless
is unable to reach the plasma membrane. In fact, a
fusion protein of construct 2 ⁄1 with enhanced green
fluorescent protein joined to the C-terminus demon-
strated strong intracellular expression and also did not
display any specific surface [3H]BK binding activity
(not shown). All other constructs with mutations made
in ICL-2 were strongly expressed. The mutants made
in ICL-3 all revealed high expression levels, with the
exception of mutant 3 ⁄ 5, positioned at the C-terminus
of ICL-3, which displayed only 6% of that obtained
for B2RwtH.
These results demonstrate that the ICLs, in particu-
lar ICL-1, the conserved DRY sequence at the N-ter-
minus of ICL-2 and the C-terminus of ICL-3, play a
crucial role in the self-maintenance of the receptor,
and that small changes in amino acid composition of
the sequences can significantly affect the number of
receptors reaching the cell surface. So far, however,
our data allow no conclusion to be drawn (except for
construct 2 ⁄ 1) on the cause of the different expression
levels observed.
Mutations in ICLs affect the receptor ligand
binding site
The receptor equilibrium binding affinity (Kd) reflects
the conformation of the extracellular ligand binding
site. Differences in the affinities displayed by the
expressed mutant constructs may therefore indicate dif-
ferent preferences in coupling to intracellular proteins,
such as G proteins, arrestins or receptor kinases,
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Fig. 2. Construct expression levels. (A) Maximal surface binding of
[3H]BK to confluent monolayers of HEK 293 cells stably and isogen-
ically expressing the indicated constructs was estimated with
approximately 30 nM [3H]BK on ice, as described in Materials and
methods. The data shown are the mean ± SEM of at least three
clones determined in duplicate. The positions of the amino acids
mutated to Ala are given in parentheses. Open columns, expres-
sion of the constructs under the control of the CMV promoter; filled
columns, HA-tagged constructs under the control of the weaker
Pmin promoter. (B) Immunoblot of B2Rwt, mutant 2 ⁄ 1 and the N-
glycosylation-deficient mutant N3 ⁄ 12 ⁄ 180H. HEK 293 cells stably
expressing high (B2RwtH) or low (B2RwtL) amounts of HA-tagged
wild-type B2R, construct 2 ⁄ 1 or mutant N3 ⁄ 12 ⁄ 180H were lysed in
RIPA buffer, as described in Materials and methods, and treated or
not with PNGase as indicated; 15 lg (only 5 lg of B2RwtH) of pro-
tein was separated by SDS–PAGE and detected by western blot
using a monoclonal HA antibody. The relative molecular masses of
standard proteins are indicated on the left side in kilodaltons. The
blot shown is representative of two experiments.
Ala screening of intracellular loops of the B2 receptor A. Faussner et al.
4 FEBS Journal (2009) ª 2009 The Authors Journal compilation ª 2009 FEBS
because such interactions can also affect the overall
receptor conformation, including the binding site.
Most GPCRs respond to an agonist at higher tempera-
tures with receptor sequestration. As a consequence,
Kd values are usually determined either in intact cells
on ice or at a suitable temperature (4–37 !C) in whole-
cell lysates or membrane preparations. One disadvan-
tage of the former approach is that receptors barely
signal at 4 !C. By contrast, a disadvantage of the latter
approach is that interacting proteins that become
recruited from the cytosol after receptor activation
may either be too diluted (whole-cell lysates) or be no
longer present at all (membrane preparations). There-
fore, as an alternative, we have established a method
[14] whereby, through the inhibition of receptor
sequestration by pretreatment of the cells with pheny-
larsine oxide (PAO), we can determine the Kd value at
37 !C (and at 4 !C) in whole intact cells with all cyto-
solic proteins present.
At 37 !C, B2RwtL displayed an affinity for [3H]BK
of 8.05 ± 1.10 nm. This was increased to 2.02 ±
0.22 nm (n = 5) when incubations were performed on
ice, corresponding to an approximately four-fold
increase in affinity (Fig. 3, Table 1). A similar pattern
was seen for B2RwtH, although both affinities were
slightly lower (10.42 ± 1.56 and 2.81 ± 0.7 nm,
respectively). Mutants 1 ⁄ 2 and E66A showed a higher
affinity than B2RwtL at 37 !C (3.21 ± 0.31 and
3.77 ± 0.67 nm, respectively), but also showed a four-
fold shift to higher affinity when incubated on ice
(0.79 ± 0.11 and 0.94 ± 0.29 nm, respectively), thus
retaining their higher affinity relative to B2Rwt at both
temperatures. In contrast, mutant 2 ⁄ 2 in ICL-2 dis-
played a high affinity at 37 !C, but exhibited almost no
shift to higher affinity on ice (2.96 ± 0.74 nm at 37 !C
versus 1.8 ± 0.36 nm at 4 !C), suggesting that this
mutant is in a high-affinity state at 37 !C. The other
mutants in ICL-2 displayed affinity increases at 4 !C
relative to 37 !C that were similar to those observed for
B2Rwt (Fig. 3).
With the exception of mutant 3 ⁄ 3, all constructs
generated in ICL-3 displayed a binding behavior
clearly different from that of B2Rwt. Although the
mutations located in the middle of ICL-3 (constructs
3 ⁄ 2 and 3 ⁄4) and T242A showed affinities at 37 !C
that were similar to those determined for B2Rwt, they
did not respond to incubation at 4 !C with an increase
in affinity as pronounced as that seen for B2Rwt, dis-
playing a shift of less than two-fold. The constructs at
either the N-terminal (mutant 3 ⁄ 1) or C-terminal
(mutant 3 ⁄ 5) end of ICL-3 exhibited a high affinity at
37 !C and at 4 !C (Fig. 3, Table 1).
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Fig. 3. Equilibrium dissociation constants Kd
at 37 and 4 !C. Binding of [3H]BK (0.01–
30 nM) to HEK 293 cells stably expressing
the indicated constructs was determined at
37 and 4 !C after inhibition of receptor
sequestration by pretreatment of the cells
with 100 lM PAO, as described in Materials
and methods. Two representative binding
curves are shown: (A) construct 1 ⁄ 1; (B)
construct 2 ⁄ 2. (C) Kd values of all constructs
as mean ± SEM of at least three experi-
ments (results also given in Table 1). Open
symbols, Kd values at 37 !C; filled symbols,
Kd values at 4 !C. Note the logarithmic scale
of the y-axis. Comparison between Kd val-
ues at 37 and 4 !C: *P < 0.05; **P < 0.01;
***P < 0.001; ns, not significant.
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As these differences in binding affinity could not be
caused by a direct effect of the mutations on [3H]BK
binding, they must be induced allosterically through
changes in the overall structure of the receptor. Thus,
these data demonstrate the connection between the
structure of ICLs and that of the binding site, implying
reciprocally that changes at the binding site through
binding of an (inverse) agonist could also induce con-
formational changes in the ICLs, as required for signal
transduction.
Basal activity and stimulated accumulation of IPs
Stimulation of B2Rwt leads to activation of phospho-
lipase C via G protein Gq ⁄ 11, resulting in the release of
inositol trisphosphate. In order to determine the effects
of the loop mutations on the interaction of the recep-
tor with Gq ⁄ 11, we measured the accumulation of IPs
in the presence of 50 mm LiCl with and without stimu-
lation by BK for 30 min. The fact that some of the
mutants did not show a strong difference in their affin-
ities at 37 and 4 !C (see Fig. 3) suggests that they
might be in a permanently higher affinity state, i.e.
have a semi-active conformation. If so, they could
either exhibit a higher basal activity or display a strong
signal in response to even poor partial agonists. As
mentioned previously, the pseudopeptides icatibant
(also known as Hoe140 or Je049) and B9430 were
partial agonists at B2RwtH, but were not able to elicit
an IP response when the receptors were expressed at a
lower level, comparable with B2RwtL (Fig. 4). Thus,
these drugs provide a tool for the identification of
semi-active mutants, provided that these constructs are
expressed at lower levels. To meet this requirement, we
expressed the constructs also under the control of the
weaker Pmin promoter, in case we observed a response
to B9430 and icatibant at expression levels higher than
7 pmol receptorÆ(mg protein))1. As this was the case
for the constructs 3 ⁄2, 3 ⁄ 4 and T242A (data not
shown), we used them for IP experiments at the lower
expression levels, as depicted in Fig. 2A.
The activation of most constructs by 1 lm BK
induced an 8–15-fold increase over basal IP, deter-
mined as the amount of IP in cells kept on ice (Fig. 4,
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Fig. 4. Basal and stimulated accumulation
of total IPs. Cells in 12-well plates were
preincubated overnight with 0.5 lCi [3H]ino-
sitol. IP accumulation (basal and stimulated)
in the presence of 50 mM LiCl after incuba-
tion for 30 min at 37 !C with 1 lM of the
indicated peptides was determined as
described in Materials and methods. Each
value represents the mean ± SEM of at
least three independent experiments
performed in duplicate. The results are
presented as the fold increase over the IP
content of identically treated control cells
that had remained on ice. Basal (black
columns), BK (open columns), B9430
(hatched columns), icatibant (grey
columns). #Use of cells expressing
smaller amounts of the constructs under
the control of the Pmin promoter [mutant
3 ⁄ 2, 4.0 ± 0.2 pmolÆ(mg protein) )1; mutant
3 ⁄ 4, 6.0 ± 0.4 pmolÆ(mg protein) )1; mutant
T242A, 3.8 ± 0.5 pmolÆ(mg protein) )1].
Comparison between basal and stimulated
IP accumulation: *P < 0.05; **P < 0.01;
***P < 0.001.
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open columns; Table 1). In our experimental set-up,
there appears to be no direct linear correlation
between the induced accumulation of IPs and the
amount of expressed receptors, as demonstrated by the
example of B2Rwt (see Table 1), where an almost five-
fold higher expression of surface receptors [11.0 versus
2.4 pmolÆ(mg protein))1] did not result in a signifi-
cantly higher IP response (12.55 ± 1.00-fold versus
12.11 ± 1.22-fold over the basal level). This suggests
that, at these levels, the receptor number is not limiting
for the maximal response, and that most of the over-
expressed receptors are not directly coupled to signal
transduction. To avoid an over-interpretation of the
data, we attempted only a semi-quantitative evaluation
of the IP data. Some results, however, require some
comment. For example, all mutants made in ICL-1
(1 ⁄ 1, 1 ⁄ 2, E66A) had an apparently strong signal rela-
tive to their expression level, particularly mutant 1 ⁄ 2
and point mutant E66A. A similar signal, however,
was obtained when an inducible B2Rwt was expressed
at the same low levels using the Flp-In ⁄Trex expression
system (A. Faussner et al., unpublished results). In
contrast, mutant 3 ⁄ 5, which expressed at the same low
levels, showed almost no response at all, suggesting
a pivotal role for this sequence (or part of it) in the
coupling to and ⁄or activation of Gq ⁄ 11.
When stimulated with 1 lm of the partial agonists
B9430 and icatibant, most of the mutants did not
respond with increased IP accumulation. However, in
two mutants in ICL-3 (3 ⁄4 and T242A), exposure to
these compounds resulted in a significant increase in
accumulated IPs (Fig. 4), suggesting that these muta-
tions result in a semi-active receptor conformation
with regard to Gq ⁄ 11 activation. The mutated
sequences therefore apparently contribute to keeping
the receptor in an inactive state, but are not solely
responsible for regulating the activation state, as none
of these mutations resulted in increased basal, ago-
nist-independent activity of the receptor (Fig. 4,
Table 1).
EC50 of IP accumulation
There was no significant difference in the EC50 values
obtained with B2Rwt expressed at two different levels,
demonstrating that, at these levels, the efficiency of
BK is independent of the number of receptors (Fig. 5,
Table 1). In all the mutants made in ICL-1, BK dis-
played efficiencies similar (1 ⁄ 1) or apparently even
higher (1 ⁄ 2, E66A) than those observed in B2Rwt, in
agreement with their higher binding affinities at 37 !C
(see Fig. 3).
Of the constructs generated in ICL-2, mutants 2 ⁄ 3
and 2 ⁄ 4 showed a strongly increased EC50 value
(approximately 15-fold) when compared with B2Rwt
(Fig. 5, Table 1). As these constructs displayed maximal
responses similar to that of B2Rwt (see Fig. 4), these
results indicate that constructs 2 ⁄ 3 and 2 ⁄4 display
weaker coupling of Gq ⁄ 11, but do not lack in general the
ability to fully activate the G protein.
All cluster mutations of ICL-3, but not point muta-
tion T242A, exhibited a tendency to reduced efficiency,
but this failed to achieve statistical significance. These
results, combined with the lower maximal responses
(Fig. 4), suggest that the sequences at the N-terminus
and in the middle of ICL-3 may participate in the
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Fig. 5. EC50 values of IP accumulation.
Cells were treated and incubated as
described in the legend of Fig. 4 with
increasing concentrations of BK
(10)12–10)5 M) for 30 min at 37 !C, and the
determination of total IPs was performed as
described in Materials and methods. EC50 is
given as the mean ± SEM of the number of
experiments indicated in Table 1. Note the
logarithmic scale of the y-axis. Comparison
with EC50 values of both high and low
B2Rwt: ***P < 0.001.
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coupling and activation of Gq ⁄ 11. As a result of its lack
of activity, no EC50 value could be obtained for
mutant 3 ⁄ 5.
Internalization of [3H]BK
After stimulation, most GPCRs, including B2Rwt,
become sequestered to compartments within the cell.
Recent publications have indicated that the ICLs of
GPCRs might not only be involved in the interaction
with their cognate G proteins, but may also serve,
together with (phosphorylated) Ser ⁄Thr residues in the
C-terminal tail, as contact sites for arrestins and
GRKs. Thus, these loops may also contribute to recep-
tor internalization [10,15]. In addition, diminished or
increased ability to interact with the cognate G pro-
tein(s), or a changed capability to activate them, might
also affect this process through steric hindrance. There-
fore, we also examined the capabilities of the various
constructs to internalize [3H]BK. Having demonstrated
recently that the internalization decreases when too
many receptors are occupied in cells with high receptor
expression [16], we took care to use nonsaturating con-
centrations of less than 2 nm [3H]BK. Under these con-
ditions, none of the constructs exhibited significantly
slower internalization than that observed for B2Rwt
(Fig. 6). This suggests that the amino acid residues
involved are not of pivotal significance for internaliza-
tion. As a result of its lack of surface binding activity,
no results could be obtained for mutant 2 ⁄1, i.e. partic-
ipation of the highly conserved DRY sequence in the
internalization process cannot be excluded by our data.
Discussion
The goal of the present study was to identify residues
and regions in the intracellular domains of human B2R
that play a major role in its signal transduction and
sequestration processes – specifically, regions that are
involved in interactions with G proteins, receptor kin-
ases or arrestins. To this end, and in order to avoid
any bias by focusing only on highly conserved resi-
dues, we set out to systematically mutate all three
ICLs. To reduce the amount of constructs, we started
with the generation of 12 cluster mutations (three to
five amino acids) and two point mutants. Our use
of the Flp-In system (Invitrogen) guaranteed stable
isogenic expression, and thus allowed direct compari-
son of the expression levels of the various constructs
without having to take into account a possible differ-
ent insertion into the genome of the host cell line
affecting the expression level per se. In total, only one
mutant (construct 2 ⁄ 1) of the 14 constructs displayed
no binding activity at all; several others exhibited low
expression, but still signaled well, and only one mutant
(construct 3 ⁄ 5) did not signal at all, despite detectable
binding.
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Fig. 6. Internalization of [3H]BK. Cells expressing B2Rwt or the indi-
cated receptor constructs were preincubated with 2 nM [3H]BK for
90 min on ice. Internalization was started by warming the plates to
37 !C in a water bath. At the given time points, surface-bound and
internalized [3H]BK were determined by acetic acid treatment, as
described in Materials and methods. Internalization is given as a
percentage of total bound [3H]BK (surface plus internalized [3H]BK).
Data points represent the mean ± SEM of at least three experi-
ments performed in duplicate or triplicate.
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All mutations in ICL-1 resulted in a strong decrease
in binding without affecting either receptor signaling
or sequestration. These results are in agreement with
reports on rat B2R [17] as well as rhodopsin [18],
indicating that ICL-1 forms a tight bend, the distur-
bance of which strongly affects the receptor expression
level. Thus, ICL-1 is important for the maintenance of
the overall receptor structure and stability, but is
apparently of no functional importance otherwise.
Regions in ICL-2 and ICL-3 appear to play a substan-
tial role in the correct processing and trafficking of the
receptor, as demonstrated by the overall lower surface
expression levels of the mutants generated in these
loops. Constructs 3 ⁄ 5 and 2 ⁄ 1, in particular, displayed
little or no surface binding, respectively. Each of these
two regions includes negatively and positively charged
amino acids that might be crucial for correct folding.
Of particular interest are the two residues R128 in
sequence 2 ⁄1 and E238 in sequence 3 ⁄ 5 (Figs 1 and 7)
that are highly conserved in many family A GPCRs. It
has been postulated that they form an ‘ionic lock’ that
upholds the inactive state of the receptor by stabilizing
it [19]. A similar stabilizing role in B2R might explain
why mutation of the regions containing these residues
strongly affects surface expression.
Our results indicate that ICL-2 and ICL-3 are
strongly involved in the interaction with Gq ⁄ 11, but in
different ways. Mutations in ICL-2 resulted in a clear
reduction in signaling potency (more than 10-fold), but
not in a significantly reduced maximal response, sug-
gesting that the sequences mutated participate in the
coupling to Gq ⁄ 11 but not in its activation. The notion
of impaired coupling of ICL-2 mutants is also sup-
ported by the fact that, despite their high expression
levels, mutants 2 ⁄ 3–2 ⁄ 5 could not be activated by
B9430 or icatibant, in contrast with B2RwtH. In addi-
tion, they also displayed the lowest basal activities of
all constructs, hinting at an inverse agonistic effect of
these mutations regarding the activation of Gq ⁄ 11. The
cluster mutation 3 ⁄ 4 and point mutation T242A in
ICL-3, in contrast, resulted in semi-active receptor
conformations, as these expressed constructs gave a
clear response to these otherwise poor partial agonists.
Our observation that semi-active conformations do not
necessarily result in increased basal activity (Fig. 4)
has also been reported for bovine rhodopsin, where
the mutation of Tyr to Ala in the highly conserved
NPXXY sequence did not result in increased basal
activity, but turned a poor agonist into a potent one
[20].
Looking at the affinities of the mutants at 37 and
4 !C, only three constructs (1 ⁄ 1, 2 ⁄ 3 and 3 ⁄ 3) showed
binding characteristics comparable with those observed
for B2Rwt. All other mutants differed significantly at
either 4 or 37 !C, demonstrating that mutations in
ICLs also affect the conformation of the extracellular
binding site. Whether these different Kd values are
inherent properties of the mutants caused by a change
in the overall receptor conformation, or reflect modi-
fied interactions with cytosolic proteins stabilizing
certain receptor conformers, will require further study.
A strong reduction in the affinity shift [Kd(37 !C) ⁄
Kd(4 !C) £ 2] apparently points to a semi-active recep-
tor conformation, as two constructs with a weak affin-
ity shift (3 ⁄ 4 and T242A; Fig. 3, Table 1) responded
well to poor partial agonists with the accumulation of
IPs (Fig. 4). This indicates a role for the respective
sequences in maintaining the receptor in an inactive
state and preventing unwanted interaction and activa-
tion of Gq ⁄ 11. Intriguingly, homology modeling of
B2Rwt using the Expasy Proteomics Server software
deep view, employing the structure of inactive rhodop-
sin (Protein Data Bank access code PDB 1U19) as a
template, resulted in a three-dimensional structure that
displayed the regions relevant for semi-activity clearly
separated from those related to potency reduction
(Fig. 7). These latter sequence types, such as the muta-
tions in constructs 2 ⁄ 4 and 2 ⁄ 5, apparently contribute
to the coupling of the receptor to G protein Gq ⁄ 11. A
look at the acidic, negatively charged surface of G pro-
tein heterotrimers [21] might explain these results.
These regions contain positively charged residues
(K134 in 2 ⁄ 3 and R140 ⁄R142 in 2 ⁄ 4), whereas one
mutation resulting in a semi-active conformation is
missing a negative charge (E234 in 3 ⁄ 4) that might
serve to repel, to a certain degree, the negatively
charged G proteins in the inactive state.
Although a role of ICLs in receptor internalization
has been reported for other family A GPCRs [10,22],
no significant differences were observed between
B2Rwt and the loop mutants regarding their internali-
zation of [3H]BK. These results are consistent with our
previous observation that the intracellular C-terminus
is crucial for ligand-induced receptor internalization
[23]. Swapping the C-terminal tails between B1R and
B2R was sufficient to transfer the capability to undergo
rapid ligand-induced receptor internalization to B1R, a
receptor which, in its wild-type state, does not become
internalized in response to agonist stimulation [24].
However, we cannot exclude the possibility that the
effects of the mutations on interactions with either
receptor kinases or arrestins were not sufficiently
strong to be detected under the conditions used. Alter-
natively, it is possible that the region pivotal for these
interactions is the DRY sequence that could not be
investigated in this regard, because of a lack of surface
A. Faussner et al. Ala screening of intracellular loops of the B2 receptor
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binding of the triple mutant. Results with the CXCR5
receptor do, indeed, suggest binding of arrestins to the
region of the DRY sequence [15]. The fact that con-
struct 3 ⁄5 has minimal capacity to stimulate Gq ⁄ 11
(Fig. 4), but nevertheless becomes sequestered as
quickly as B2Rwt (Fig. 6), indicates that G protein
activation and receptor internalization are two inde-
pendent processes, i.e. sequestration of the receptor
is not a consequence of a prior activation of the G
protein.
In summary, our results show that changes in ICL-1
strongly affect receptor surface expression, but not
receptor signaling or receptor sequestration. Even
more important for receptor maintenance are the
DRY sequence at the N-terminus of ICL-2 and the
TERR sequence at the C-terminus of ICL-3, as cluster
mutations here complete abolish (construct 2 ⁄1) or
strongly reduce (construct 3 ⁄5) surface receptor expres-
sion. Both ICL-2 and ICL-3 are involved in the inter-
action with G protein Gq ⁄ 11, but in different ways.
Sequences in ICL-2 apparently contribute more to the
coupling, and regions in ICL-3 preferentially to the
activation, of Gq ⁄ 11. None of the three ICLs appears
to have a crucial function in the sequestration process,
i.e. in the interaction with receptor kinases and ⁄or
arrestins, with the caveat that, as a result of experi-
mental reasons, no conclusion can yet be drawn on
the role of the highly conserved DRY sequence at the
N-terminus of ICL-2. Our results obtained with the
cluster mutations indicate that certain sequences need
to be investigated in more detail, and will therefore be
targeted in future studies for the generation of point
mutants.
Materials and methods
Materials
Flp-In! TREx-293 (HEK 293) cells were obtained from
Invitrogen. [2,3-Prolyl-3,4-3H]BK (2.96 TBqÆmmol)1) and
myo-[2-3H]inositol (0.81 TBqÆmmol)1) were obtained from
PerkinElmer Life Sciences (Boston, MA, USA). BK was
purchased from Bachem (Heidelberg, Germany). B9430 and
icatibant were generous gifts from J. Stewart (Denver, CO,
USA) and Jerini (Berlin, Germany), respectively. Roche
(Mannheim, Germany) delivered Fugene. Poly-d-lysine,
captopril, 1,10-phenanthroline and bacitracin were pur-
chased from Aldrich (Taufkirchen, Germany). Fetal calf
serum, culture media, hygromycin B and penicillin ⁄ strepto-
mycin were obtained from PAA Laboratories (Cölbe,
Germany). Primers were synthesized by Invitrogen and
delivered desalted and lyophilized.
Gene mutagenesis, expression and cell culture
Standard PCR techniques with primers designed accord-
ingly and the B2Rwt gene as template were used to generate
point- or cluster-mutated versions of B2Rwt. In each case,
successful mutation was verified by sequencing (Medigeno-
mix, Martinsried, Germany). The coding sequences of
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Fig. 7. Position of mutations and annotation
of their effects in a computational model of
B2R as seen from the cytosol. The structure
was generated with SWISS-model [26]
based on the crystal structure of bovine rho-
dopsin in its inactive form (PDB 1U19A
[27]). Dark blue, cytosolic ends of the seven
transmembrane helices I–VII and cytosolic
helix VIII; point and cluster mutants are
depicted in black and white, as also shown
in Fig. 1 (only a-carbon chain, no side-chains
shown, with the exception of R128 in blue
and E238 in red); grey, amino acids not
mutated outside of helices; green boxes,
effect of indicated mutations on receptor
properties.
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B2Rwt and all mutants started with the third encoded Met
[11], and were cloned into the HindIII and XhoI sites of the
pcDNA5 ⁄FRT vector (Invitrogen). Most of the receptor
sequences were preceded at the N-terminus by a double tag
(MGRSHHHHHHGYPYDVPDYAGS), with the last two
amino acids (Gly-Ser) of the tag being generated by the
insertion of a BamHI site. A few constructs were tagged
with a single HA tag (MGYPYDVPDYAGS) wherever
indicated. The nature of the tags did not influence the phar-
macological properties of the constructs. For stable expres-
sion of the constructs, we used the Flp-In system from
Invitrogen, in which the vector containing the gene of inter-
est is inserted at a unique locus into the genome of the spe-
cial host cell line Flp-In! TREx-293 (HEK 293) through
the transient concomitant expression of the recombinase
pOG44. HEK 293 cells, cultivated in DMEM supplemented
with 10% fetal calf serum and penicillin ⁄ streptomycin, were
transfected using the transfection reagent Fugene (Roche)
following the instructions of the manufacturer. Single stably
expressing clones resulted after selection with 250 lgÆmL)1
hygromycin B. For experiments requiring repeated rinsing
of the cells, poly-d-lysine-treated (0.01% in NaCl ⁄Pi) cell
culture dishes were used to ensure adherence.
Equilibrium binding experiments at 37 and 4 "C
For the determination of the equilibrium binding affinity
constant Kd at 4 "C and, in particular, at 37 "C, receptor
sequestration was inhibited by pretreatment of the cell
monolayers in 48 wells with 100 lm PAO in incubation
buffer (40 mm Pipes, 109 mm NaCl, 5 mm KCl, 0.1% glu-
cose, 0.05% BSA, 2 mm CaCl2, 1 mm MgCl2, pH 7.4) for
5 min at 37 "C, as published previously [14]. Thereafter, the
cells were rinsed three times with ice-cold NaCl ⁄Pi, 0.2 mL
of incubation buffer with degradation inhibitors (2 mm baci-
tracin, 0.8 mm 1,10-phenanthroline and 100 lm captopril)
containing increasing concentrations of [3H]BK (from
approximately 0.01 to 30 nm) was added and the cells were
immediately warmed to 37 "C in a water bath. For the
determination of the affinities at 37 "C, the incubation was
stopped after 30 min by placing the trays on ice and rinsing
the cells four times with ice-cold NaCl ⁄Pi. Surface-bound
[3H]BK (> 95% of totally bound radioactivity in cells pre-
treated with PAO) was dissociated by a 10 min incubation
with 0.2 mL of an ice-cold dissociation solution (0.2 m ace-
tic acid–0.5 m NaCl, pH 2.7), transferred to a scintillation
vial and counted in a b-counter after the addition of scintil-
lation fluid. For determination of the affinities at 4 "C, the
initial 30 min incubation at 37 "C was followed by an addi-
tional incubation on ice. After 90 min, these cells were also
rinsed with ice-cold NaCl ⁄Pi and [3H]BK binding was mea-
sured as described above. Nonspecific binding was deter-
mined in the presence of 5 lm of unlabeled BK and
subtracted from the total binding determined with [3H]BK
alone to calculate the specific binding.
Determination of total IP release
Monolayers of stably transfected HEK 293 cells on 12 wells
were incubated overnight with 0.5 mL complete medium
containing 1 lCi [3H]inositolÆmL)1. The cells were washed
twice with NaCl ⁄Pi and pre-incubated for 90 min on ice in
incubation buffer supplemented with 50 mm LiCl with or
without the addition of increasing concentrations (10)12–
10)5 m) of BK. Stimulation was started by placing the cells
in a water bath at 37 "C and continued for 30 min. The
accumulation of total IPs was terminated by exchanging
the buffer for 0.75 mL of ice-cold 20 mm formic acid solu-
tion. After 30 min on ice, another 0.75 mL of formic acid
solution, followed by 0.2 mL of a 3% ammonium hydrox-
ide solution, were added. The mixture was applied to AG
1-X8 anion exchange columns (Biorad, Munich, Germany;
2 mL volume). The columns were washed with 1 mL of
1.8% ammonium hydroxide and 9 mL of 60 mm sodium
formate ⁄ 5 mm tetraborate buffer, followed by 0.5 mL of
4 m ammonium formate ⁄ 0.2 m formic acid. Total IPs were
finally eluted in 2 mL of the latter buffer and counted in a
b-counter after the addition of scintillation liquid.
Immunoblotting
Monolayers in six-well trays were washed three times with
NaCl ⁄Pi and solubilized in RIPA buffer (50 mm Tris ⁄HCl,
150 mm NaCl, 1% Nonidet P-40, 0.5% sodium deoxycho-
late, 0.1% SDS, 2 mm EDTA, pH 7.5) including 0.5 mm Pe-
fabloc SC and 10 lm each of 1,10-phenathroline, aprotinin,
leupeptin and pepstatin A for 30 min at 4 "C with gentle
agitation. The lysate was centrifuged at 6240 g for 15 min at
4 "C. The supernatant (protein concentration, !1 mgÆmL)1)
was treated with PNGase (Roche, Mannheim, Germany)
for 2 h at 37 "C as indicated, mixed with Laemmli buffer
and incubated for 10 min at 70 "C. Following electrophore-
sis (!15 lg total protein per lane unless stated otherwise)
on 4–12% SDS–polyacrylamide gels, the fractionated pro-
teins were electroblotted onto 0.45 lm nitrocellulose. The
membrane was blocked for 1 h at 4 "C with 5% milk pow-
der in washing buffer (Tris-buffered saline, pH 7.5, 0.1%
Tween 20), and incubated overnight with primary anti-HA
high-affinity IgG (1 : 2000) added in fresh blocking buffer.
After washing the membrane three times, each for 10 min,
the secondary peroxidase-labeled anti-rat Ig (1 : 2000) was
added for 1 h at room temperature in blocking buffer.
Finally, the membrane was washed again three times, each
for 10 min, before antibody binding was detected using wes-
tern blot Chemiluminescence Reagent Plus (Perkin-Elmer
Life Sciences, Boston, MA, USA).
[3H]BK internalization
Cells on multiwell plates (24 well ⁄ 48 well) were rinsed
three times with NaCl ⁄Pi and incubated with 0.2 mL of
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approximately 2 nm [3H]BK in incubation buffer for
90 min on ice in order to obtain equilibrium binding.
[3H]BK internalization was started by placing the plates in
a water bath at 37 !C. The internalization process was
stopped at the indicated times by putting the plates back
on ice and washing the cells four times with ice-cold
NaCl ⁄Pi. Subsequently, surface-bound [3H]BK was dissoci-
ated by incubating the cell monolayers for 10 min with
0.2 mL of ice-cold dissociation solution. The remaining
monolayer with internalized [3H]BK was lysed in 0.2 mL of
0.3 m NaOH and transferred with another 0.2 mL water to
a scintillation vial. The radioactivity of both samples was
determined in a b-counter after the addition of scintillation
fluid. Nonreceptor-mediated [3H]BK surface binding and
internalization were determined in the presence of 5 lm
unlabeled BK and subtracted from total binding to calcu-
late the specific values. Internalization was expressed as the
amount of internalized [3H]BK as a percentage of the com-
bined amounts of internalized and surface-bound [3H]BK.
Protein determination
Total protein was quantified with the Micro BCA Protein
assay reagent kit from Pierce (Rockford, IL, USA) using
BSA as standard.
Data analysis
All data analysis was performed using graphpad prism for
Macintosh, Version 4.0c (GraphPad Software, Inc., San
Diego, CA, USA). Data were assessed by appropriate analy-
sis of variance (ANOVA), with subsequent post hoc analysis
using the Student–Newman–Keuls test. Alternatively, paired
t-tests were used as indicated.
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